SSRIのすべて

出版社： 先端医学社
著者：
発行日： 2007-10-30
分野： 臨床医学：内科  >  精神医学
ISBN： 9784884074241
電子書籍版： 2007-10-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,475 円(税込)

購入する

商品紹介

治療薬を日常臨床にいかに応用すべきか、あらゆる角度からその可能性を探り、EBMから治療戦略までも網羅した薬剤の使い方の実践書。

目次

  • SSRIのすべて

    ―目次―

    Part 1／総論
    1．現代社会におけるうつ病の問題と SSRI の意義
    2．SSRI 開発の歴史と治療への臨床応用

    Part 2／SSRI の臨床薬理
    1．セロトニントランスポーターの機能異常と阻害効果
    2．SSRI の作用とセロトニン濃度
    3．SSRI と脳機能?脳イメージングから?
    4．SSRI の薬物動態と代謝
    　　?フルボキサミン，パロキセチンを中心に?
    5．SSRI の脳由来神経栄養因子（BDNF）への作用

    Part 3／SSRI による治療の実際
    ?／SSRI による気分障害へのアプローチ
    A：うつ病性障害
    1．うつ病治療薬としての SSRI の位置づけ
    2．軽症うつ病と SSRI の効果
    3．難治性うつ病に対する SSRI の効果
    4．非定型うつ病の病態と SSRI の効果
    5．うつ病の再燃・再発と SSRI の効果
    6．EBM からみた SSRI のうつ病への治療効果
    7．プライマリ・ケアと SSRI

    B．双極性うつ病における SSRI の効果
    C．季節性うつ病における SSRI の効果

    II／SSRI による不安障害へのアプローチ
    1．社会不安障害
    2．パニック障害
    3．強迫性障害
    4．PTSD

    III／SSRI による身体症状・疾患へのアプローチ
    1．慢性疼痛
    2．呼吸器障害
    3．過敏性腸症候群
    4．摂食障害
    5．循環器障害?虚血性心疾患を中心として?
    6．うつ病と糖尿病

    Part 4／SSRI の投与法の実際
    1．SSRI と投与量，投与期間の原則
    2．SSRI と服薬アドヒアランス
    3．SSRI の長期投与における効果
    4．中止後発現症状の観点からみた SSRI の使い方
    5．薬物療法以外の治療と SSRI の併用効果
    　　　?精神療法の併用を中心として?
    6．他剤から SSRI へ切り替える際の注意点
    7．老年者のうつ病における SSRI の使い方

    Part 5／治療上の注意点と安全性
    1．SSRI の安全性・副作用・薬物相互作用?その対策
    2．SSRI の退薬症候と投与中止時の原則
    3．SSRI の児童・青年期患者への投与と安全性

    Part 6／将来展望
    1．うつ病・不安障害における SSRI の今後の役割と使い方
    　　　?ベンゾジアゼピンと比較して
    2．医療経済学からみた SSRI
    3．SSRI と患者へのサイコエデュケーション
    4．時間生物学的な治療からみた SSRI

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part1 / 総論

P.25 掲載の参考文献
1) Murray CJ, Lopez AD:Global burden of disease:A comprehensive assessment of mortality and morbidity from diseases, injuries and risk factors in 1990 and projected to 2020, vol 1. Harvard:World Health Organization, 1996
 
2) World Health Organization http://www.who.int/en/
 
3) 上島国利:うつ病アカデミーの設立から日本うつ病学会の発足まで. 三田評論 2003年12月号
 
4) Santarelli L, Saxe M, Gross C et al:Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809, 2003
PubMed
5) Grunebaum MF, Ellis SP, Li S et al:Antidepressants and suicide risk in the United States 1985-1999. Clin Psychiatry 65:1456-1462, 2004
PubMed
6) Mann JJ, Apter A Bertolote J et al:Suicide prevention strategies:a systematic review. JAMA 294:2064-2074, 200
 
7) Martinez C Rietbrock S, Wise L et al:Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression nested case-control study. BMJ 330:389, 2005
 
8) Friedman RA, Leon AC:Expanding the black box-depression antidepressants and the risk of suicide. N Engl Med 356:343-2346, 2007
 
9) Bridge JA, Iyengar S, Salary CB et al:Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment a meta-analysis of randomized controlled trials. JAMA 297 1683-1696, 2007
PubMed
10) Juurlink DN Mamdani MM Kopp A et al:The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813-821, 2006
PubMed
11) 坂元薫:妊娠・出産・授乳期におけるうつ病の治療ストラテジー. 臨床精神薬理 7:1889-1894, 2004
 
12) Kallen B:Neonate characteristics after maternal use of antidepressants in late pregnancy Arch Pediatr Adolesc Med 158:312-316, 2004
PubMed
13) Hallberg P, Sjoblom V:The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding:a review and clinical aspects. J Clin Psychopharmacol 25:59-73, 2005
PubMed
14) PAXIL(R) prescribing information. http://us.gsk.com/products/assets/us_paxil.pdf
 
15) Williams M, Wooltorton E:Paroxetine (Paxil) and congenital malformations. CMAJ 173:1320-1321, 2005
PubMed
16) Wogelius P, Norgaard M, Munk EM et al:Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiol Saf 14:S72, 2005
 
17) Therapeutic Goods Administration. Safeguarding public health & safety in Australia by regulating medicines medical devices blood & tissues. Information for health professionals concerning use of SSRI antidepressants in pregnant women. http://www.tga.health.gov.au/alerts/ssri-hp.htm
 
18) Chambers CD, Hernandez-Diaz S, Van Marter LJ et al Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl Med 354:579-587, 2006
PubMed
19) Cohen LS, Altshuler LL, Harlow BL et al:Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499-507, 2006
PubMed
20) Fairman KA, Teitelbaum E Drevets WC et al:Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents:a comparison in managed care and fee for-service environments. Am J Manag Care 3:453-465, 1997
 
21) Cantrell CR, Eaddy MT, Shah MB et al:Methods for evaluating patient adherence to antidepressant therapy:a real-world comparison of adherence and economic outcomes. Med Care 44:300-303, 2006
PubMed
22) Taylor CB Youngblood ME, Catellier D et al:Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792-798, 2005
PubMed
23) Ruhe HG Huyser J, Swinkels JA et al:Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder a systematic review. J Clin Psychiatry 67:1836-1855, 2006
PubMed
P.37 掲載の参考文献
1) Kline NS:Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol 19 (suppl 1):S72-S78, 1958
 
2) West ED, Dally PJ:Effects of iproniazid in depressive syndromes. Br Med J 13:1491-1494, 1959
 
3) 村崎光邦:うつ病における MAO 阻害薬復活の可能性. 神経精神薬理 11:763-779, 1989
 
4) Kuhn R:The treatment of depression with G-22355 (imipramine hydrochloride). Am J Psychiatry 115:450-464, 1957
 
5) Coppen AJ:Serotonin in affective disorders. In:Factors in Depression. ed. by Kline NS Raven Press New York 1974 pp. 34-35
 
6) Schildkraut JJ:The catecholamine hypothesis of affective disorders a review of suppoting evidence. Am Psychiattry 122:509-522 1965
 
7) 村崎光邦:SSRIとうつ病. 神経精神薬理 17:239-255 1995
 
8) 村崎光邦:SSRIの臨床. 脳と精神の科学 7:53-65 1996
 
9) 村崎光邦:SSRIへの期待. 臨床精神薬理 2:691-710 1999
 
10) 平松謙一, 高橋良, 森温理 ほか:多施設共同二重盲検法による zimelidine と imipramineのうつ病に対する臨床的有用性の比較. 精神医学 25:1341-1350 1983
 
11) 村崎光邦. 森温理, 浅井昌弘 ほか:選択的セロトニン再取り込み阻害薬 SME3110 (fluvoxamine maleate) のうつ病, うつ状態に対する前期臨床第II相試験. 臨床精神薬理 1:185-198 1998
 
12) 村崎光邦, 森温理 山下格 ほか:選択的セロトニン再取り込み阻害薬 SME3110 (fluvoxamine maleate) のうつ病およびうつ状態に対する臨床後期第II相試験-塩酸イミプラミンを対照とした用量範囲の検討-. 臨床医薬 14:919-949 1998
Medical*Online
13) 村崎光邦 森温理, 三浦貞則 ほか:選択的セロトニン再取り込み阻害薬 SME3110 (fluvoxamine maleate) のうつ病, うつ状態に対する臨床評価-塩酸アミトリプチリンとの二重盲検比 較試験-. 臨床医薬 14:951-980 1998
Medical*Online
14) 並木正義 谷口由輝 奥瀬哲 ほか SME3110 (fluvoxamine maleate) の内科領域におけるうつ患者に対する臨床第III相試験-塩酸トラゾドン対照薬とした二重盲検比較試験. 臨床医薬 12:243-260, 1996
 
15) 中嶋照夫, 工藤義雄, 山下格 ほか:選択的セロトニン再取り込み阻害薬SME3110 (fluvoxamine maleate) の強迫性障害に対する後期臨床第II相試験-プラセボ対照二重盲検試験による用量ならびに有効性の検証-. 臨床医薬14:589-616 1998
 
16) Asakura S Tajima O Koyama T Fluvoxamine treatment of generalized social anxiety disorder in Japan a randomized double-blind placebo-controlled study Int Neuropschopharmacol 10:263-274 2007
PubMed
17) 村崎光邦:Fluvoxamineの基礎と臨床. 臨床精神薬理 2:763-776 1999
 
18) Lassen JB:Potent and long-lasting Potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur J Pharmacol 47:351-358 1978
PubMed
19) 村崎光邦:Paroxetineの基礎と臨床. 臨床精神薬理 3:949-974 2000
 
20) 村崎光邦, 石郷岡純, 高橋明比古 ほか:セロトニン選択的再取り込み阻害薬SI211103の第I相試験. 薬理と治療 14:185-251 1986
 
21) 村崎光邦, 高橋明比古, 井之川芳之 ほか:塩酸パロキセチンの第I相臨床試験 (第2報)-健常成人男子に塩酸パロキセチン20mgを単回および1日1回10日間反復経口投与した時の薬物動態に関する検討. 薬理と治療 28 (suppl):S37-S46, 2000
 
22) 村崎光邦, 高橋明比古, 角田貞治 ほか:塩酸パロキセチンの第I相臨床試験 (第1報)-健常成人男子に塩酸パロキセチン20mgを単回および1日1回10日間反復経口投与した時の安全性および臨床薬理学的検討. 薬理と治療 28 (suppl):S7-S36, 2000
 
23) 三浦貞則, 山下格, 浅井昌弘 ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのうつ病およびうつ状態に対する臨床評価-塩酸イミプラミンを対照とした用量設定試験薬理と治療 28 (suppl):S137-S160, 2000
 
24) 三浦貞則, 小山司, 浅井昌弘 ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのうつ病およびうつ状態に対する臨床評価-塩酸アミトリプチリンを対照とした二重盲検群間比較試験薬理と治療 28 (suppl):S187-S210, 2000
 
25) 筒井未春, 奥瀬哲, 佐々木大輔 ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのうつ病およびうつ状態に対する臨床評価-塩酸トラゾドンを対照とした二重盲検群間比較試験-. 薬理と治療 28 (suppl):S161-S185, 2000
 
26) 筒井未春, 小山司, 奥瀬哲 ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのパニック障害に対する臨床評価-第III相二重盲検群間比較試験薬理と治療 28 (suppl) S295-S314, 2000
 
27) 上島国利, 村崎光邦, 浅井昌弘 ほか:塩酸パロキセチン水和物 (パキシル(R)) の強迫性障害に対する臨床評価-プラセボを対照とした二重盲検比較試験-. 薬理と治療32:577-591 2004
 
28) 上島国利, 小山司, 三田俊夫 ほか:選択的セロトニン再取り込み阻害薬塩酸セルトラリンのうつ病およびうつ状態に対する臨床評価-塩酸アミトリプチリンを対照薬とした二重盲検 比較試験-. 神経精神薬理 19:529-548, 1997
 
29) 筒井未春 奥瀬哲 佐々木大輔 ほか塩酸セルトラリン (選択的セロトニン再取り込み阻害薬) のうつ病およびうつ状態に対する臨床評価-塩酸トラゾドンを対照薬とした二重盲検 群間比較試験-. 神経精神薬理 19:549-568,8 1997
 
30) Kamijima K, Burt T, Cohen G et al:A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 21:1-9 2006
 
31) Kamijima K, Kuboki T, Kumano H et al A placebo-controlled randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 20:265-273 2005
PubMed
32) Murdoch D, Keam S:Escitalopram:a review of its use in the management of majir depressive disorder drugs 65:2379-2404, 2005
PubMed
33) Waugh J Goa KL Escitalopram. A review of its use in the management of major depressive and anxiety disorders. CNS Drugs 7:345-362, 2003
 
34) Boyer WF, Feighner JP:Other uses of the serotonin selective reuptake inhibitors in psychiatry. In:Selective Serotonin Re-UPtake Inhibitors. 2nd ed Advances in Basic Research and Clinical Practice, ed. by Feighner JP, Boyer WF, John Wiley & Sons Ltd, New York, 1996, pp.267-289
 
35) Stahl SM:Antidepressants:the blue-chip psychotropic for the modern treatment of anxiety disorders.J Clin Psychiatry 60:356-357, 1999
PubMed
36) Narrow WE, Rae DS, Robins LN et al:Revised prevalence estimates of mental disorders in the United States using a clinical significance criterion to reconcile 2 survey's estimates. Arch Gen Psychiatry 59:115-123, 2002
 

Part2 / SSRIの臨床薬理

P.43 掲載の参考文献
1) Murphy DL, Lerner A, Rudnick G et al:Serotonin transporter:gene, genetic disorders, and pharmacogenetics. Mol Interv 4:109-123, 2004
PubMed
2) Nakamura M, Ueno S, Sano A et al:The human serotonin transporter gene linked polymorphism (5-HTTLPR) show ten novel allelic variants. Mol Psychiatry 5:32-38, 2000
PubMed
3) Hu XZ, Lipsky RH, Zhu G et al:Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826, 2006
PubMed
4) Neumeister A, Konstantinidis A, Stastny J et al:Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 59:613-620 2002
PubMed
5) Hariri AR, Mattay VS, Tessitore A et al:Serotonin transporter genetic variation and the response of the human amygdala. Science 297:400-403 2002
PubMed
6) Heinz A, Braus DF, Smolka MN et al:Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8:20-21, 2005
PubMed
7) Anguelova M, Benkelfat C, Turecki G:A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter:I. Affective disorders. Mol Psychiatry 8:574-591, 2003
PubMed
8) Cho HJ, Meira-Lima I, Cordeiro Q et al:Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder:a systematic review and meta-analysis. Mol Psychiatry 10:771-781, 2005
PubMed
9) Lasky-Su JA, Faraone SV, Glatt SJ et al:Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 133:110-115, 2005
 
10) Anguelova M, Benkelfat C, Turecki G:A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter:II. Suicidal behavior. Mol Psychiatry 8:646-653, 2003
PubMed
11) Lin PY, Tsai G:Association between serotonin transporter gene promoter polymorphism and suicide:results of a meta-analysis. Biol Psychiatry 55:1023-1030, 2004
PubMed
12) Sen S, Burmeister M, Ghosh D:Meta-analysisof the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 127:85-89, 2004
 
13) Schinka JA, Busch RM, Robichaux-Keene N:A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9:197-202, 2004
PubMed
14) Munafo MR, Clark T, Flint J:Does measurement instrument moderate the association between the serotonin transporter gene and anxiety-related personality traits? A meta-analysis. Mol Pschiatry 10:415-419 2005
 
15) Ozaki N, Goldman D, Kaye WH et al:Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 8:895, 933-936, 2003
 
16) Delorme R, Betancur C, Wagner M et al:Support for the association between the rare functional variant I425 V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Mol Psychiatry 10:1059-1061, 2005
 
17) Lesch KP, Gutknecht L:Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29:1062-1073, 2005
PubMed
18) Rausch JL:Initial conditions of psychotropic drug response studies of serotonin transporter long promoter region (5-HTTLPR) serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Prog Neuropsychopharmacol Biol Psychiatry 29:1046-1061, 2005
PubMed
19) Bennett AJ, Lesch KP, Heils A et al:Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry 7:118-122, 2002
PubMed
20) Champoux M, Bennett A, Shannon C et al:Serotonin transporter gene polymorphism differential early rearing and behavior in rhesus monkey neonates. Mol Psychiatry 7:1058-1063, 2002
PubMed
21) Caspi A, Sugden K, Moffitt TE et al:Influence of life stress on depression:moderation by a polymorphism in the 5-HTT gene. Science 301:386-389, 2003
PubMed
P.48 掲載の参考文献
1) Frazer A:Serotonergic and noradrenergic reuptake inhibitors:prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62 (suppl 12):S16-S23, 2001
 
2) Heydorn WE:Paroxetine a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders. Expert Opin Investig Drugs 8:417-441, 1999
PubMed
3) Bymaster FP, Zhang W, Carter PA et al:Fluoxetine but not other selective serotonin reuptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160:353-361, 2002
 
4) Hirano K, Kimura R, Sugimoto Y et al:Relationship between brain serotonin transporter binding plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144:695-702, 2005
PubMed
5) 笹征史:セロトニン受容体の役割受容体の種類関与する疾患について. 医薬ジャーナル 36:1383-1388, 2000
 
6) Agnati LF, Zoli M, Stromberg I et al:Intercellular communication in the brain:wiring versus volume transmission. Neuroscience 69:711-726, 1995
PubMed
7) Anderson GM, Bennett AJ, Weld KP et al:Serotonin in cisternal cerebrospinal fluid of rhesus monkeys basal levels and effects of sertraline administration. Psychopharmacology (Berl) 161:95-99, 2002
PubMed
8) Tanda G, Bassareo V, Di Chiara G:Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology (Berl) 123:127-130, 1996
 
9) 小山司, 高橋義人, 井上猛ほか抗うつ薬による前頭葉皮質ドーパミン系の選択的活性化作用に関する研究 (I) 厚生省精神・神経疾患研究5年度研究報告書感情障害の神経科学的 成因及び治療に関する研究 1994, pp.95-100
 
10) Bhagwagar Z, Wylezinska M, Taylor M et al:Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161:368-370, 2004
PubMed
11) Shioda K, Nisijima K, Yoshino T et al:Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcy promine and fluoxetine. Prog Neuropsychopharcol Biol Psychiatry 28:633-640, 2004
 
12) Doya K:Metalearning and neuromodulation. Neural Netw 15:495-506, 2002
PubMed
P.54 掲載の参考文献
1) Buchsbaum MS. Wu J, Siegel BV et al:Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 41:15-22, 1997
PubMed
2) Mayberg HS, Brannan SK, Tekell JL et al:Regional metabolic effects of fluoxetine in major depression serial changes and relationship to clinical response. Biol Psychiatry 48:830-843, 2000
PubMed
3) Kennedy SH, Evans KR, Kruger S et al:Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am Psychiatry 158:899-905, 2001
PubMed
4) Mayberg HS:Modulating dysfunctional limbiccortical circuits in depression:towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65:193-207, 2003
PubMed
5) Saxena S, Brody AL, Ho ML et al:Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 59:250-261, 2002
PubMed
6) Messa C, Colombo C, Moresco RM et al:5-HT (2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls:a PET study. Psychopharmacology (Berl) 167:72-78 2003
PubMed
7) Meyer JH Kapur S Houle S et al Prefrontal cortex 5-HT2 receptors in depression an [18F] setoperone PET imaging study Am J Psychiatry 156:1029-1034 1999
PubMed
8) Yatham LN, Liddle PF, Dennie J et al:Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment:a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 56:705-711 1999
PubMed
9) Massou JM, Trichard C, Attar-Levy D et al:Frontal 5-HT2 A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl) 133:99-101 1997
 
10) Moresco RM Colombo C Fazio F et al:Effects of fluvoxamine treatment on the in vivo binding of [F-18] FESP in drug naive depressed patients:a PET study Neuroimage 12:452-465, 2000
PubMed
11) Zanardi R, Artigas F, Moresco R et al:Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment:a positron emission tomography scan study. J Clin Psychopharmacol 21:53-58, 2001
PubMed
12) Meyer JH Kapur S, Eisfeld B et al:The effect of paroxetine on 5-HT (2 A) receptors in depression:an [(18) F] setoperone PET imaging study.Am J Psychiatry 158:78-85, 2001
 
13) Drevets WC Frank E Price JC et al:Serotonin type-1A receptor imaging in depression. Nucl Med Biol 27:499-507, 2000
PubMed
14) Sargent PA. Kjaer KH, Bench CJ et al:Brain serotonin 1 A receptor binding measured by positron emission tomography with [11C] WAY-100635:effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-180, 2000
PubMed
15) 大久保善朗, 須原哲也:受容体占有と抗精神病作用-PET/SPECTを用いた抗精神病薬の薬効評価-. 精神神経学雑誌 103:329-340, 2001
 
16) Meyer JH, Wilson AA, Ginovart N et al:Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression:a [ (11) C] DASB PET imaging study. Am J Psychiatry 158:1843-1849, 2001
PubMed
17) Kent JM, Coplan JD, Lombardo I et al:Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia:a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berl) 164:341-348, 2002
PubMed
18) Meyer JH, Wilson AA Sagrati S et al:Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses:an [11C] DASB positron emission tomography study.Am J Psychiatry 161:826-835, 2004
PubMed
19) Suhara T, Takano A, Sudo Y et al:High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60:386-391, 2003
PubMed
20) Takahashi H, Yahata N, Koeda M et al:Effects of dopaminergic and serotonergic manipulation on emotional processing:a pharmacological fMRI study. Neuroimage 27:991-1001, 2005
PubMed
P.61 掲載の参考文献
1) DeVane CL:Differential pharmacology of newer antidepressants. J Clin Psychiatry 59 (suppl 20):S85-S93, 1998
 
2) Greenblatt DJ:Drug interactions with newer antidepressants:role of human cytochrome P450. J Clin Psychiatry 59 (suppl 15):S19-S27, 1998
 
3) DeVane CL, Gill HS:Clinical pharmacokinetics of fluvoxamine:applications to dosage regimen design. J Clin Psychiatry 58 (suppl 5):S7-S14, 1997
 
4) PDR:Physicians' Desk Reference, 1998 (52nd edition) ed. by J. Paul Folsman, Medical Economics Company, Oradell, NJ, 1998, pp.2891-2894
 
5) Lam YW, Gaedigk A, Ereshefsky L et al:CYP2D6 inhibition by selective serotonin reuptake inhibitors:analysis of achievable steady state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22:1001-1006, 2002
PubMed
6) 石郷岡純:選択的セロトニン再取り込み阻害薬SME3110 (fluvoxamine maleate) の第I相試験.臨床評価 21:441-490, 1993
 
7) 岡五百理:選択的セロトニン再取り込み阻害薬SME3110 (fluvoxamine maleate) のうつ病, うつ状態に対する臨床評価-長期投与試験-. 臨床医薬 12:471-487, 1996
Medical*Online
8) Hiemke C, Hartter S:Pharmacokinetics of serotonin reuptake inhibitors. Pharmacol Ther 85:11-28, 2000
PubMed
9) Dudek D, Zieba A, Siwek M et al:Selective serotonin reuptake inhibitors-current knowledge. Psychiatr Pol 38:507-524, 2004
PubMed
10) Carrillo JA, Dahl ML, Svensson JO et al:Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183-190, 1996
PubMed
11) Spina E, Scordo MG:Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19:299-320, 2002
 
12) 筒井末春 選択的セロトニン再取り込み阻害薬SME3110 (fluvoxamine maleate) の高齢者のうつ病, うつ状態に対する臨床試験. 臨床薬理 12:261-275, 1996
 
13) 坂本孝司 井之川芳之 成田裕保:塩酸パロキセチンの第I相臨床試験 (第6報). 薬理と治療 28 (suppl):S111-S118, 2000
 
14) PDR:Physicians' Desk Reference, 1998 (52nd edition), ed. by J. Paul Folsman, Medical Economics Company, Oradell, NJ, 1998, pp.2851-2856
 
15) Sindrup SH, Brosen K, Gram LF:Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine. Clin Pharmacol Ther 51:288-295, 1992
PubMed
16) Sawamura K, Suzuki Y, Someya T:Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60:553-557, 2004
PubMed
17) 村崎光邦, 高橋明比古, 井之川芳之:塩酸パロキセチンの第I相臨床試験 (第2報). 薬理と治療 28 (suppl):S37-S46, 2000
 
18) Kotzailias N, Marker M, Jilma B:Early effects of paroxetine on serotonin storage, plasma levels and urinary excretion:a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 24:536-539, 2004
 
19) 小林一広, 村崎光邦, 稲見充昭:選択的再取り込み阻害薬塩酸パロキセチンの肝機能・腎機能低下のうつ病患者における薬物動態試験. 薬理と治療 28 (suppl):S237-S252, 2000
 
20) Golden RN:Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol Bull 37 (suppl 1):S176-S186, 2003
 
21) 上島国利:塩酸セルトラリン (CP-51, 974-1) 第I相試験-単回投与試験-. 神経精神薬理 19:395-423, 1997
 
22) 上島国利:塩酸セルトラリン (CP-51, 974-1) 第I相試験-反復投与試験-. 神経精神薬理 19:425-447, 1997
 
23) 上島国利:塩酸セルトラリンの薬物動態に及ぼす食事の影響. 神経精神薬理 19:461-470, 1997
 
24) Reis M, Aberg-Wistedt A, Agren H et al:Serum disposition of sertraline, N-desmethylsertraline and paroxetine:a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 19:283-291, 2004
 
25) Hamelin BA:The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60:512-521, 1996
 
26) DeVane CL, Liston HL, Markowitz JS:Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247-1266, 2002
PubMed
27) PDR:Physicians' Desk Reference, 1998 (52nd edition), ed. by J. Paul Folsman, Medical Economics Company, Oradell NJ, 1998, pp.2229-2234
 
28) MacQueen G, Born L, Steiner M:The selective serotonin reuptake inhibitor sertraline:its profile and use in psychiatric disorders. CNS Drug Rev 7:1-24, 2001
PubMed
29) 上島国利:塩酸セルトラリンの高齢者うつ病に対する臨床試験-高齢者に対する臨床的有用性および薬物動態の検討-. 神経精神薬理 19:569-585, 1997
 
30) PDR:Physicians' Desk Reference, 1998 (52nd edition), ed. by J. Paul Folsman, Medical Economics Company, Oradell, NJ, 1998, pp.859-863
 
31) Henry ME, Schmidt ME, Hennen J et al:A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine:A 19-F MRS study. Neuropsychopharmacology 30:1576-1583, 2005
 
32) Wernicke JF:Safety and side effect profile of fiuoxetine. Expert Opin Drug Saf 3:495-504, 2004
PubMed
33) Hall J, Naranjo CA, Sproule BA et al:Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 23:349-357, 2003
PubMed
34) Gury C, Cousin F:Pharmacokinetics of SSRI antidepressants:half-life and clinical applicability. Encephale 25:470-476, 1999
PubMed
35) von Moltke LL:Human cytochromes mediating N-demethylation of fluoxetine in vivo. Psychopharmacology 132:402-407, 1997
 
P.67 掲載の参考文献
1) Yoshimura R, Nakamura J, Shinkai K et al:Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels:mini review. Prog Neuropsychopharmacol Biol Psychiatry 28:611-616, 2004
PubMed
2) Shinkai K, Yoshimura R, Toyohira Y et al:Effect of prolonged exposure to milnacipran on norepinephrine transporter in cultured bovine adrenal medullary cells. Biochem Pharmacol 70:1389-1397, 2005
PubMed
3) Ueda N, Yoshimura R, Nakamura J:Fluvoxamine improves some depressive symptoms by influencing noradrenergic neurons. Psychiatry Res, in Press
 
4) Shinkai K, Yoshimura R, Ueda N et al:Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24:11-17, 2004
PubMed
5) Yoshimura R, Ueda N, Nakamura J:Successful treatment of steroid-induced depression with low dosage of fluvoxamine. Aust NZ J Psychiatry 35:855-856, 2001
 
6) Smith MA Makino S Kvetnansky R et al Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. Neurosci 15:1768-1777 1995
PubMed
7) Nibuya M, Morinobu S, Duman RS:Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Neurosci 15:7539-7547, 1995
PubMed
8) Pan W, Banks WA, Fasold MB et al:Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacol 37:1553-1561, 1998
 
9) Karege F, Schwald M, Cisse M:Postnatal development profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261-264, 2002
PubMed
10) Karege F, Perret G, Bondolfi G et al:Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109:143-148, 2002
PubMed
11) Shimizu E, Hashimoto K, Okuma N et al:Alteration of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75, 2003
PubMed
12) 吉村玲児, 堀輝, 岡本龍也ほか:BDNFはうつ状態の生物学的マーカーになりうるか? 第25回躁うつ病の薬理・生化学的研究懇話会 長崎 抄録集 2006
 
13) Karege F, Bondolfi G, Gervasoni N et al:Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57:1068-1072, 2005
PubMed
14) Yukimasa T, Yoshimura R, Tamagawa A et al:High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39:52-59, 2006
PubMed
15) Zanardini R, Gazzoli A, Ventriglia M et al:Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 91:83-86, 2006
PubMed
16) Lang UE, Bajbouj M, Gallinat J et al:Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacol (Berl) 187:56-59, 2006
 
17) Aydemir O, Deveci A, Taneli F:The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients:a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29:261-265, 2005
PubMed
18) Gonul AS, Akdeniz F, Taneli F et al:Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255:381-386, 2005
PubMed
19) Aydemir C, Yalcin ES, Aksaray S et al:Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 30:1256-1260, 2006
PubMed

Part3 / SSRlによる治療の実際

P.75 掲載の参考文献
1) Kahn A, Warner HA, Brown WA:Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials:an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317, 2000
 
2) 米国精神医学会治療ガイドライン大うつ病性障害. 監訳;日本精神医学会責任訳者;樋口輝彦 医学書院 東京 2000. pp.15-22 (American Psychiatric Association Practice guideline for major depressive disorder in adults. Am J Psychiatry 150:1-26, 1993)
 
3) Song F, Freemantle N, Sheldon TA et al:Selective serotonin reuptake inhibitors meta-analysis of efficacy and acceptability. BMJ 306:683-687, 1993
PubMed
4) Canadian Coordinating Office for Health Technology Assessment:Selective Serotonin Reuptake Inhibitors for Major Depression. Part 1, ed. by Trindade E, Melon D, CCOHTA report, 1997 (上島国利, 尾鷲登志美:うつ病の薬物療法. 臨床 精神医学29:1039-1048, 2000)
 
5) Agency for Health Care Policy and Research:Treatment of depression newer pharmacotherapies. AHCPR Publication No.99-E014. 1999 (http://www.ahcpr.gov/clinic/index.html#evidence)
 
6) Danish University Antidepressant Group:Citalopram:clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 90:131-138, 1986
PubMed
7) Anderson IM:Selective serotonin reuptake inhibitors versus tricyclic antidepressants of efficacy and tolerability. J Affect Disord 58:19-36, 2000
 
8) Geddes JR, Freemantle N, Mason J et al:Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review). In:the Cochrane Library, Issue 3, Oxford, Update Software, 2001
 
9) Lopez-Ibor J, Guelfi JD, Pletan Y et a:Milnacipran and selective serotonin reuptake inhibitors in major. Int Clin Psychopharmacol 11 (suppl 4):S41-S46, 1996
 
10) Ballus C, Quiros G, de la Torre J et al:The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 15:43-48, 2000
PubMed
11) Costa e Silva J:Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59:352-357, 1998
PubMed
12) Poirier MF, Boyer P:Venlafaxine and paroxetine in treatment-resistant depression. Double-blind randomised comparison. Br,J Psychiatry 175:12-16, 1999
PubMed
13) Silverstone P, Ravindram A:Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 60:22-28, 1999
 
14) Smith D, Dempster C, Glanville J:Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants:a meta-analysis. Br J Psychiatry 180:396-404, 2002
PubMed
15) WFSBP版:単極性うつ病性障害の生物学的治療ガイドライン.山田和男訳, 星和書店, 東京, 2003 (Bauer M, Whybrow PC, Angst J et al:WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders.2002
 
16) Healy D, Aldred G:Antidepressant drug use & the risk of suicide. Int Rev Psychiatry 17:163-172, 2005
PubMed
17) Kent JM:SNaRIs, NaSSAs and NaRIs:new agents for the treatment of depression. Lancet 355:911-918, 2000
PubMed
18) Stahl SM, Nierenberg AA, Gorman JM:Evidence of early onset of antidepressant effect in randomized controlled trials. Clin Psychiatry 62 (suppl 4):S17-S23, 2001
 
19) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressantactivity and clinical tolerability Int Clin Psychopharmacol 12:99-108, 1997
PubMed
20) Clerc G;Milnacipran/Fluvoxamine Study Group:Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor:a comparison with fluvoxamine. Int Clin Psychopharmacol 16:145-151, 2001
 
21) Thase ME, Entsuah AR, Rudolph RL:Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241, 2001
PubMed
22) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitorsin major. Int Clin Psychopharmacol 11 (suppl 4):S41-S46, 1996
 
23) Poirier ME Boyer P Venlafaxine and paroxetine in treatment-resistant depression. Doubleblind randomised comparison. Br J Psychiatry 175:12-16, 1999
 
24) Mehtonen OP, Sogaard J, Roponen P et al:Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 61:95-100, 2000
 
25) Thase ME, Friedman ES, Howland RH:Venlafaxine and treatment-resistant depression. Depress Anxiety 12 (suppl 1):S55-S62, 2000
 
26) 塩江邦彦, 平野雅己, 神庭重信:大うつ病性障害の治療アルゴニズム. 気分障害の薬物治療アルゴニズム, 精神科薬物療法研究会, 本橋伸高 編, じほう, 東京, 2003
 
27) Bech P, Cialdella P, Haugh MC et al:Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 176:421-428, 2000
PubMed
28) Bauer M Dopfmer S:Lithium augmentation in treatment-resistant depression:meta-analysisof placebo-controlled studies. J Clin Psychopharmacol 19:427-434, 1999
 
29) Danish University Antidepressant Group:Paroxetine a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18:289-299, 1990
 
P.82 掲載の参考文献
1) Hotopf M, Hardy R, Lewis G:Discontinuation rates of SSRIs and tricyclic antidepressants a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170:120-127, 1997
PubMed
2) Preskorn SH:Unterschiede zwischen den SSRIs als Gruppe und TZAs. Klinische Pharmakologie der selektiven Serotonin-Wiederaufnahmehemmer, 1. Auflage (Nachdruck), Professional Communications, Inc., Caddo, OK, USA, 1997, pp.75-89
 
3) Anderson IM:Selective serotonin reuptake inhibitors versus tricyclic antidepressants:a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36, 2000
 
4) Trindade E, Menon D:Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part I:Evaluation of the clinical literature. Ottawa:Canadian Coordinating Office for Health Technology Assessment. Report 3E, 1997
 
5) Kasper S Heiden A:Do SSRIs differ in their antidepressant efficacy Hum Psychopharmacol 10 (suppl):S163-S172, 1995
 
6) Fawcett J, Barkin RL:Efficacy issues with antidepressants. J Clin Psychiatry 58 (suppl 6):S32-S39, 1997
 
7) Stuppaeck CH, Geretsegger C, Whitworth AB et al:A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 14:241-246, 1994
PubMed
8) Montgomery SA:A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 6:169-178, 2001
 
9) 石郷岡純:SSRIの効果. 臨床精神薬理 2:737-746, 1999
 
10) 大坪天平, 上島国利, 鳥居成夫 ほか:SSRIs の臨床応用. 臨床精神薬理 2:747-754, 1999
 
11) The American Psychiatric Association:Quick Reference to the Diagnostic Criteria from DSM-IV-TR, The American Psychiatric Association, Washington D. C., 2000 (高橋三郎, 大野裕, 染矢俊幸訳:DSM-IV-TR 精神疾患の分類と診断の手引, 医学書院, 東京, 2002)
 
12) 塩江邦彦, 平野雅己, 神庭重信:大うつ病性障害の治療アルゴリズム. 気分障害の薬物治療アルゴリズム, 精神科薬物療法研究会, 本橋伸高 編, じほう, 東京, 2003, pp.19-46
 
13) 久保田正春, 篠原学, 加賀美真人 ほか:我が国における大うつ病 (非精神病性) に対する薬物療法の現状分析-薬物療法研究会の調査結果から-. 精神医学 39:1169-1173, 1997
 
14) Corruble E, Guelfi JD:Does increasing dose improve efficacy in patients with poor antidepressant response:a review. Acta Psychiatr Scand 101:343-348, 2000
PubMed
15) Thase ME, Blomgren SL, Birkett MA et al:Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J CIin Psychiatry 58:16-21, 1997
 
16) Joffe RT, Levitt AJ, Sokolov ST et al:Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 57:114-115, 1996
 
17) American Psychiatric Association:Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (suppl 4):S1-S45, 2000
 
18) Keller MB:The long-term treatment of depression. J Clin Psychiatry 60 (suppl 17):S41-S45, 1999
 
19) Doogan DP, Caillard V:Sertraline in the prevention of depression. Br J Psychiatry 160:217-222, 1992
PubMed
20) Terra JL, Montgomery SA:Fluvoxamine prevents recurrence of depression:results of a long-term, double-blind placebo-controlled study. Int Clin Psychopharmacol 13:55-62, 1998
PubMed
P.90 掲載の参考文献
1) Anderson IM:Selective serotonin reuptake inhibitors versus tricyclic antidepressants:a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36 2000
 
2) American Psychiatric Association:Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (4 Suppl):S1-S45, 2000
 
3) 塩江邦彦, 平野雅巳, 神庭重信:大うつ病性障害の治療アルゴリズム. 気分障害の薬物療法アルゴリズム, 精神科薬物療法研究会編, じほう, 東京, 2003, pp.19-46
 
4) Thase ME, Rush AJ:Treatment-resistant depression. In:Psychopharmacology:The Fourth Generation of Progress, ed. by Bloom FE, Kupfer DJ, Raven Press, New York, 1995, pp.1081-1097
 
5) Quitkin FM, McGrath PJ, Stewart JW et al:Remission rates with 3 consecutive antidepressant trials:effectiveness for depressed outpatients. J Clin Psychiatry 66:670-676, 2005
PubMed
6) 井上猛 小山司:三環系・四環系抗うつ薬に治療抵抗性うつ病の定義の妥当性に関する研究-第二選択の三環系・四環系抗うつ薬への変更は有効な治療戦略か-. 臨床精神医学 26:1603-1607, 1997
Medical*Online
7) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (suppl 4):S41-S46, 1996
 
8) Thase ME, Entsuah AR, Rudolph RL:Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241, 2001
PubMed
9) 一宮哲哉 大久保善朗, 荒川亮介ほか:抗うつ薬によるセロトニンおよびノルアドレナリントランスポーター占有率に関するPET研究. 精神薬療基金研究年報 38:35-39, 2006
 
10) Meyer JH, Wilson AA, Sagrati S et al:Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses:an [11C] DASB positron emission tomography study. Am J Psychiatry 161:826-835, 2004
PubMed
11) Ichimiya T, Suhara T, Sudo Y et al:PET study of affective disorders and evaluation of treatments. In:In Recent advances in the research of affective disorders in Japan, Elsevier Science, 東京, 2002, pp.63-73
 
12) White K, Wykoff W, Tynes LL et al:Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr J Univ Ott 15:156-158, 1990
PubMed
13) Peselow ED, Filippi AM, Goodnick P et al:The short-and long-term efficacy of paroxetine HCl:B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 25:272-276, 1989
 
14) Suhara T, Takano A, Sudo Y et al:High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60:386-391, 2003
PubMed
15) Danish University Antidepressant Group:Paroxetine:a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18:289-299, 1990
 
16) Thase ME, Rush AJ, Howland RH et al:Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59:233-239, 2002
PubMed
17) Nolen WA, van de Putte JJ, Dijken WA et al:Treatment strategy in depression. 1. Nontri-cyclic and selective reuptake inhibitors in resistant depression:a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 78:668-675, 1988
 
18) Delgado PL, Price LH, Charney DS et al:Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15:55-60, 1988
PubMed
19) Poirier MF, Boyer P:Venlafaxine and paroxetine in treatment-resistant depression. Double-blind randomised comparison. Br J Psychiatry 175:12-16, 1999
PubMed
20) 井上猛, 北市雄士, 小山司:治療抵抗性うつ病の治療戦略とその作用機序. 日本精神神経学雑誌 106:1016-1023, 2004
 
21) Rush AJ, Trivedi M, Fava M:Depression, IV:STAR*D treatment trial for depression. Am J Psychiatry 160:237, 2003
 
22) Trivedi MH, Rush AJ, Wisniewski SR et al:Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice. Am J Psychiatry 163:28-40, 2006
 
23) Rush AJ, Trivedi MH, Wisniewski SR et al:Bupropion-SR sertraline or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242, 2006
 
24) Papakostas GI, Petersen T, Worthington JJ et al:A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol 18:293-296, 2003
PubMed
25) Gagiano CA, Muller PG, Fourie J et al:The therapeutic efficacy of paroxetine:(a) an open study in patients with major depression not responding to antidepressants;(b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand 80 (suppl 350):S130-S131, 1989
 
P.98 掲載の参考文献
1) West ED, Dally PJ:Effects of iproniazid in depressive syndromes. Br Med J 1:1491-1494, 1959
PubMed
2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, fourth ed., Text Revision, APA, Washington D. C., 2000
 
3) Stewart JW, McGrath PJ, Rabkin JG et al:Atypical depression:a valid clinical entity? Psychopharmacology 16:479-495, 1993
 
4) Parker G, Roy K, Mitchell P et al:Atypical depression:a reappraisal. Am J Psychiatry 159:1470-1479, 2002
PubMed
5) Horwath E, Johnson J, Weissman MM et al:The validity of major depression with a typical features based on a community study. J Affect Disord 26:117-126, 1992
 
6) Kendler KS, Eaves LJ, Walters EE et al:The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 53:391-399, 1996
 
7) Robertson HA, Lam RW, Stewart JN et al:Atypical depressive symptoms and cluster in unipolar and bipolar depression. Acta Psychiatr Scand 94:421-427, 1996
PubMed
8) Klein RG, Mannuzza S, Koplewicz HS et al:Adolescent depression:controlled desipramine treatment and atypical features. Depress Anxiety 7:15-31, 1998
PubMed
9) Posternak MA, Zimmerman M:Symptoms of atypical depression. Psychiatry Res 104:175-181, 2001
PubMed
10) Novick JS, Stewart JW, Wisniewski SR et al:Clinical and demographic features of atypical depression in outpatients with major depressive disorder:preliminary findings from STAR*D. J Clin Psychiatry 66:1002-1011, 2005
 
11) Nierenberg AA, Pava JA, Clancy K et al:Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biol Psychiatry 40:691-696, 1996
PubMed
12) Akiskal HS, Benazzi F:Atypical depression:a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord 84:209-217, 2005
PubMed
13) Owens MJ, Nemeroff CB:Role of serotonin in the pathophysiology of depression focus on the serotonin transporter. Clin Chem 40:288-295, 1994
PubMed
14) Asnis GM, McGinn LK, Sanderson WC:Atypical depression:clinical aspects and noradrenergic function. Am J Pschiatry 152:31-36, 1995
 
15) Posternak MA:Biological markers of atypical depression. Harv Rev Psychiatry 11:1-7, 2003
PubMed
16) Henkel V, Mergl R, Allgaier AK et al:Treatment of depression with atypical features:a meta-analytic approach. Psychiatry Res 141:89-101, 2006
PubMed
17) Lonnqvist J, Sihvo S, Syvalahti E et al:Moclobemide and fluoxetine in atypical depression:a double-blind trial. J Affect Disord 32:169-177, 1994
 
18) Pande AC, Birkett M, Fechner-Bates S et al:Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 40:1017-1020, 1996
PubMed
19) SOgaard J, Lane R, Latimer P et al:A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 13:406-414, 1999
 
20) McGrath PJ, Stewart JW, Janal MN et al:A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 157:344-350, 2000
PubMed
21) Stratta P, Bolino E, Cupillari M et al:A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 6:193-196, 1991
 
22) Joyce PR, Mulder RT, McKenzie JM et al:Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety 19:180-186, 2004
 
23) Fava M, Nierenberg AA, Quitkin FM et al:A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Pschopharmacol Bull 33:101-103, 1997
 
24) Iosifescu DV, Nierenberg AA, Mischoulon D et al:An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 66:1038-1042, 2005
PubMed
25) McGrath PJ, Stewart JW, Petkova E et al:Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 61:518-524, 2000
 
26) Zubieta JK, Pande AC, Demitrack MA:Two year follow-up of atypical depression. Psychiatr Res 33:23-29, 1999
PubMed
27) Baron R, Mufti R, Arfken C:A survey of prescribing practices for monoamine oxidase inhibitors. psychiatr Serv 50:945-947, 1999
 
28) Katona C, Livingston G:How well do antidepressants work in older people? A systematic review of number needed to treat. J Affect Disord 69:47-52, 2002
 
29) 北島明佳, 馬場元, 田村陽子 ら:低用量のselegiline (MAO-B阻害薬) が奏効した非定型うつ病の一例. 精神医学 47:681-684, 2005
 
30) Reimherr FW, Wbod DR, Byerley B et al:Characteristics of responders to fluoxetine. Psychopharmacol Bull 20:70-72, 1984
 
P.105 掲載の参考文献
1) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Major Depressive Disorder (revision). American Psychiatric Association, Washington DC, 2002
 
2) 田所千代子, 上島国利:うつ病の再燃・再発の実態. 精神科治療学 15:3-11, 2000
 
3) Rouillon F, Phillips R, Serruier D et al:Rechutes, de, depression, unipolarie et efficacite de la maprotiline. L'Encephale 15:527-534, 1989
 
4) Doogan DP, Caillard V:Sertraline in the prevention of depression. Br J Psychiatry 160:217-222, 1992
PubMed
5) Montgomery SA, Dunbar G:Paroxetine is better than placebo in relapse prevention and prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195, 1993
PubMed
6) Bump GM, Mulsant BH, Pollock BG et al:Paroxetine versus nortriptiline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 13:38-44, 2001
 
7) Lauritzen L, Odagaard K, Clemmesen L et al:Relapse prevention by means of paroxetine in ECT-treated patients with major depression:a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 94:241-251, 1996
 
8) NIMH/NIH Consensus Development Conference statement. Mood disorders:pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry 142:469-476, 1985
PubMed
9) 上島国利:うつ病の薬物療法. 臨床精神医学講座第4巻気分障害, 松下正明 編, 中山書店, 東京, 1998 pp.107-125
 
10) Frank E, Kupfer DJ, Perel JM et al:Three-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099, 1990
PubMed
11) Kupfer DJ, Frank E, Perel JM et al:Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773, 1992
PubMed
12) Lepine JP, Caillard V, Bisserbe JC et al:A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161:836-842, 2004
PubMed
13) Keller MB, Kocsis JH, Thase ME et al:Maintenance phase efficacy of sertraline for chronic depression:a randomized controlled trial. JAMA 280:1665-1672, 1998
PubMed
14) Terra JL, Montgomery SA:Fluvoxamine prevents recurrence of depression:results of long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55-62, 1998
PubMed
15) Franchini L, Gasperini M, Perez J et al:Dose-response efficacy of paroxetine in preventing depressive recurrences:a randomized, double-blind study. J Clin Psychiatry 59:229-232, 1998
PubMed
16) Franchini L, Gasperini M, Perez J et al:A double blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58:104-107, 1997
PubMed
17) Hirschfeld RM:Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 11:211-217, 1996
PubMed
P.111 掲載の参考文献
1) Ciuna A, Andretta M, Corbari L et al:Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 60:629-634, 2004
PubMed
2) グラクソ・スミスクライン:世界及び日本でのパキシル開発・使用状況. 2006. Available from:http://mrkun.m3.com/DRRouterServlet?pageFrom=CONCIERGE&operation=showMessageInDetail&pageContext=dr2.0MessageList&msgld=200606051154383244&mrId=GSK4681176&onSubmitTimeStamp=1154192656694&onLoadTimeStamp=1154192650123 (Accessed 30 July 2006)
 
3) 上島国利, 樋口輝彦 神庭重信:「うつ病の薬物療法の考え方」実態調査結果とそれを受けての提言. 日本医事新報 4262:18-24, 2005
 
4) Crismon ML, Pigott TA, Trivedi M:The Texas medication algorithm project;report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 60:142-156, 1999
PubMed
5) 塩江邦彦, 平野雅巳, 神庭重信:大うつ病性障害の治療アルゴリズム. 気分障害の薬物治療アルゴリズム, 精神科薬物療法研究会, じほう, 東京 2003, pp.19-46
 
6) 鈴木利廣, 別府宏囲, 浜六郎:臨床試験登録制度の創設と, 医薬品の承認審査に関わる非臨床及び臨床試験データの公表を求める要望書. 2005. Available from:http://www.yakugai.gr.jp/topics/file/050317ryinshoushikentourokuyoubousho.pdf (Accessed 30 July 2006).
 
7) FDA:Talk paper, FDA statement regarding the anti-depressant paxil for pediatric population. 2003. Available from http://www.fda.gov/bbs/topics/ANSWERS/2003/ANSO1230.html (Accessed 30 July 2006)
 
8) FDA:Public health advisory;Worsening depression and suicidality in patients being treated with antidepressant. March 22, 2004. Available from http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.html (Accessed 30 July 2006)
 
9) FDA:Public health advisory;Suicidality in children and adolescents being treated with antidepressant medications. October 15, 2004. Available from http://www.fda.gov/cde/drug/antidepressants/SSRIPHA200410.htm (Accessed 30 July 2006)
 
10) FDA:2006 Safety alerts for drugs, biologics, medical devices, and dietary supplements;Paxil (paroxetine hydrochloride) tablets and oral suspension paxil CR (paroxetine hydrochloride) controlled-release Tablets. 2006. Available from http://www.fda.gov/medwatch/safety/2006/safety06.htm #paxil (Accessed 30 July 2006)
 
11) Higgins JP, Green S:Cochrane handbook for systematic reviews of interventions 4.2.5. [updated May 2005], John Wiley & Sons, Ltd, Chichester, 2005
 
12) 古川壽亮:エビデンス精神医療-EBPの基礎から臨床まで, 医学書院, 東京, 2000
 
13) Guyatt G, Rennie D:User's Guide to the Medical Literature:Essentials of Evidence-Based Clinical Practice, American Medical Association, Chicago, 2001
 
14) Geddes JR, Freemantle N, Mason J et al:Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 4:CD001851, 1999
 
15) Cohen J:Statistical Power Analysis for the Behavioral Sciences (2nd edition), Lawrence Erlbaum Associates, Hillsdale, NJ, 1988
 
16) Anderson I:Selective serotonin reuptake inhibitors versus tricyclic antidepressants:a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36, 2000
 
17) Barbui C, Hotopf M, Freemantle N et al:Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev 4:CD002791, 2000
 
18) Fergusson D, Doucette S, Glass KC et al:Association between suicide attempts and selective serotonin reuptake inhibitors:systematic review of randomised controlled trials. BMJ 330:396, 2005
PubMed
19) Gunnell D, Saperia J, Ashby D:Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults:meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 330:385, 2005
 
20) GlaxoSmithKline. May 2006;IMPORTANT PRESCRIBING INFORMATION. 2006. Available from http://www.fda.gov/medwatch/safety/2006/paroxetineDHCPMay06.pdf (Accessed 30 July 2006)
 
21) 石郷岡純:SSRI-我が国におけるうつ病治療の最前線. 臨床精神薬理 8:533-551, 2005
 
22) Cipriani A, Brambilla P, Furukawa T et al:Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 4:CD004185, 2005
PubMed
23) Cipriani A, Barbui C, Brambilla P et al:Are all antidepressants really the same? The case of fluoxetine:a systematic review. J Clin Psychiatry 67:850-864, 2006
PubMed
24) Malvini L, Cipriani A, Furukawa T et al:Sertraine versus other anti-depressive agents for depression (Protocol). Cochrane Database Syst Rev 3:CD006117, 2006
 
25) Omori I, Watanabe N, Cipriani A et al:Fluvoxamine versus other anti-depressive agents for depression (Protocol). Cochrane Database Ssst Rev 4:CD006114, 2006
 
26) Watanabe N, Barbui C, Churchill R et al:Mirtazapine versus other anti-depressive agents for depression (Protocol). Cochrane Database Syst Rev 2006. submitted.
 
P.117 掲載の参考文献
1) 大坪天平:プライマリケアでうつ病を見逃さないコツ. うつ病診療のコツと落とし穴 上島国利 編, 中山書店, 東京, 2005, pp.28-29
 
2) 由良了三, 加藤誉里子, 柴原暁 ほか:二重盲検法によるsulpirideとimipramineのうつ病に対する薬効比較. 精神医学18:549-562, 1976
 
3) カプラン臨床精神医学ハンドブック, DSM-IV-TR診断基準による診療の手引き第2版, 融道男, 岩脇淳 監訳, メディカル.サイエンス.インターナショナル, 東京, 2003, p.144
 
4) Weissman MM, Pottenger M, Kleber H et al:Symptom patterns in primary and secondary depression. A comparison of primary depressives with depressed opiates addicts, alcoholics, and schizophrenics. Arch Gen Psychiatry 34:854-862, 1977
PubMed
5) 中河原通夫:内科医が知っておきたい向精神薬の選び方.使い方, 医学書院, 東京, 2004
 
6) 樋口輝彦:うつ病治療のアルゴリズム. 最新心身医学-21世紀に向けた心身医学の展開, 三輪書店, 東京, 2000, pp.176-187
 
P.121 掲載の参考文献
1) 井上猛, 田中輝明, 北市雄士ほか:双極性障害での抗うつ薬の使い方. 精神科治療学 20:1141-1149, 2005
 
2) Potter WZ:Bipolar depression:specific treatments. J Clin Psychiatry 59 (suppl 18):S30-S36, 1998
 
3) American Psychiatric Association:Practice guideline for the treatment of patients with biolar disorder (revision). Am J Psychiatry 159 (4 suppl):S1-S50, 2002
 
4) Fieve RR, Platman SR, Plutchik RR:The use of lithium in affective disorders. I. Acute endogenous depression. Am J Psychiatry 125:487-491, 1968
PubMed
5) Worrall EP, Moody JP, Peet M et al:Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 135:255-262, 1979
PubMed
6) Himmelhoch JM, Thase ME, Mallinger AG et al:Tranylcypromine vs imipramine in anergic bipolar depression. Am J Psychiatry 148:910-916, 1991
 
7) Baumhackl U, Biziere K, Fischbach R et al:Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM III):an Austrian double-blind, multicentre study. Br J Psychiatry 155:78-83, 1989
 
8) Sachs GS, Lafer B, Stroll AL et al:A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55:391-393, 1994
 
9) Prien RF, Klett CJ, Caffey EM Jr:Lithium carbonate and imipramine in prevention of affective episodes:a comparison in recurrent affective illness. Arch Gen Psychiatry 29:420-425, 1973
PubMed
10) Prien RF, Kuper DJ, Mansky PA et al:Drug therapy in the prevention of recurrences in unipolarand bipolar affective disorders:report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096-1104, 1984
 
11) Baldassano CF, Sachs GS, Stoll AL et al:Paroxetine for bipolar depression:outcome in patients failing Prior antidepressant trials. Depression 3:182-186, 1995
 
12) Young LT, Joffe RT, Robb JC et al:Double-blind comparison of additional of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124-126, 2000
 
13) Nemeroff CB, Evans DL, Gyulai L et al:Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906-912, 2001
PubMed
14) Vieta E, Martinez-Aran A, Goikolea JM et al:A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63:508-512, 2002
PubMed
15) Guy W, Wilson WH, Ban TA et al:A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull 20:73-78, 1984
PubMed
16) Cohn JB, Collins G, Ashbrook E et al:A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313-322, 1989
PubMed
17) Peet M:Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164:549-550, 1994
PubMed
18) Leverich GS, Altshuler LL, Frye MA et al:Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163:232-239, 2006
PubMed
19) Fagiolini A, Buysse DJ, Frank E et al:Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol 21:474-478, 2001
PubMed
20) 中村純:双極性障害. 気分障害の薬物治療アルゴリズム, 精神科薬物療法研究会編, じほう, 東京, 2003 pp.55-63
 
P.131 掲載の参考文献
1) Rosenthal NE, Sack DA, Gillin JC et al:Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41:72-80, 1984
PubMed
2) Blazer DG, Kessler RC, Swartz MS:Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Br J Psychiatry 172:164-167, 1998
PubMed
3) Levitt AJ, Boyle MH, Joffe RT et al:2000 Estimated prevalence of the seasonal subtype of major depression in a Canadian community sample. Can J Psychiatry 45:650-654, 2000
 
4) Sakamoto K, Kamo T, Nakadaira S et al:A nationwide survey of seasonal affective disorder at 53 outpatient university clinics in Japan. Acta Psychiatr Scand 87:258-265, 1993
PubMed
5) Okawa M, Shirakawa S, Uchiyama M et al:Seasonal variation of mood and behaviour in a healthy middle-aged population in Japan. Acta Psychiatr Scand 94:211-216, 1996
 
6) Rosen LN, Targum SD Terman M et al:Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 31:131-144, 1990
PubMed
7) Winkler D, Praschak-Rieder N, Willeit M et al:Seasonal affective depression in 2 German speaking university centers:Bonn, Vienna. Clinical and demographic characteristics. Nervenarzt 73:637-643, 2002
PubMed
8) Fernstrom JD, Wurtman RJ:Brain serotonin content increase following ingestion of carbohydrate diet. Science 174:1023-1025, 1971
PubMed
9) Fernstrom JD, Wurtman RJ:Brain serotonin content:physiological regulation by plasma neutral amino acids. Science 178:414-416, 1972
PubMed
10) Jacobsen FM, Mueller EA, Rosenthal NE et al:Behavioral responses to intravenous meta-chlorophenylpiperazine in patients with seasonal affective disorder and control subjects before and after phototherapy. Psychiatry Res 52:181-197, 1994
PubMed
11) Schwartz PJ, Murphy DL Wehr TA et al:Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. Arch Gen Psychiatry 54:375-385, 1997
PubMed
12) O'Rourke D, Wurtman JJ, Wurtman RJ et al:Treatment of seasonal depression with d-fenfluramine. J Clin Psychiatry 50:343-347, 1989
PubMed
13) McGrath RE, Buckwald B, Resnick EV:The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry 51:162-163, 1990
PubMed
14) Turner EH, Schwartz PJ, Lowe CH et al:Double-blind, placebo-controlled study of single-dose metergoline in depressed patients with seasonal affective disorder. J Clin Psychopharmacol 22:216-220, 2002
PubMed
15) Lam RW, Gorman CB, Michalon M et al:Multi-center, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 152:1765-1770, 1995
 
16) Partonen T, Lonnqvist J:Moclobemide and fluoxetine in treatment of seasonal affective disorder.J Affect disord 41:93-99, 1996
PubMed
17) Ruhrmann S, Kasper S, Hawellek B et al:Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 28:923-933, 1998
PubMed
18) Lam RW, Levitt AJ, Levitan RD et al:The Can-SAD study:a randomized controlled trial of the effectiveness of light therapy and Fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 163:805-812, 2006
PubMed
19) Wirz-Justice A, van der Velde P, Bucher A et al:Comparison of light treatment with citalopram in winter depression:a longitudinal single case study. Int Clin Psychopharmacol 7:109-116, 1992
PubMed
20) Thorell LH, Kjellman B, Arned M et al:Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacol 14 (suppl 2):S7-S11, 1999
PubMed
21) Martiny K, Lunde M, Simonsen C et al:Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand 109:230-234, 2004
PubMed
22) Moscovitch A, Blashko CA, Eagles JM et al:A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 171:390-397, 2004
PubMed
23) Modell JG, Rosenthal NE, Harriett AE et al:Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 58:658-667, 2005
PubMed
24) Pjrek E, Winkler D, Stastny J et al:Bright light therapy in seasonal affective disorder--does it suffice? Eur Neuropsychopharmacol 14:347-351, 2004
PubMed
P.139 掲載の参考文献
1) 小山司 編著:社会不安障害治療のストラテジー, 先端医学社, 東京, 2005
 
2) Schneier FR:Clinical practice. Social anxiety disorder. N Eng J Med 355:1029-1036, 2006
 
3) 笠原敏彦:対人恐怖と社会不安障害-診断と治療の指針, 金剛出版, 東京, 2005
 
4) Hedges DW, Brown BL, Shwalb DA et al:The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder:a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 21:102-111, 2007
PubMed
5) Stein DJ, Versiani M, Hair T et al:Efficacy of paroxetine for relapse prevention in social anxiety disorder:a 24-week study. Arch Gen Psychiatry 59:1111-1118, 2002
PubMed
6) Walker JR, Van Ameringen MA, Swinson R et al:Prevention of relapse in generalized social phobia results of a 24-week study in responders to 20 weeks of sertraline treatment.J Clin Psychopharmacol 20:636-644, 2000
PubMed
7) Haug TT, Blomhoff S, Hellstrom K et al:Exposure therapy and sertraline in social phobia:1-year follow-up of a randomized controlled trial. Br J Psychiatry 182:312-318, 2003
 
P.145 掲載の参考文献
1) Cowley DS, Flick SN, Roy-Byrne PP:Long-term course and outcome in panic disorder a naturalistic follow-up study. Anxiety 2:13-21, 1996
PubMed
2) Salzman C, Goldenberg I, Bruce SE et al:Pharmacologic treatment of anxiety disorders in 1989 versus 1996:results from the Harvard/Brown anxiety disorders research program. J Clin Psychiatry 62:149-152, 2001
PubMed
3) Baldwin DS, Anderson IM, Nutt DJ et al:Evidence-based guidelines for the pharmacological treatment of anxiety disorders:recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596, 2005
 
4) The National Institute for Clinical Excellence:Clinical Guideline 22. Anxiety:management of anxiety (panic disorder, with or without agora-phobia, and generalised anxiety disorder) in adults in primary, secondary and community care. December 2004
 
5) Kamijima K, Kuboki T, Kumano H et al:A placebo-controlled randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 20:265-273, 2005
PubMed
6) Bandelow B, Behnke K, Lenoir S et al:Sertraline versus paroxetine in the treatment of panic disorder:an acute double-blind noninferiority comparison. J Clin Psychiatry 65:405-413, 2004
PubMed
7) Zamorski MA, Albucher RC:What to do when SSRIs fail:eight strategies for optimizing treatment of panic disorder Am Fam Physician 66:1477-1484, 2002
 
8) Otto MW, Smits JA, Reese HE:Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 65 (suppl 5):S34-S41, 2004
 
9) Pollack MH, Simon NM, Worthington JJ et al:Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276-282, 2003
PubMed
10) Nelson J, Chouinard G:Guidelines for the clinical use of benzodiazepines:pharmacokinetics dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 6:69-83, 1999
PubMed
11) Slaap BR, den Boer JA:The prediction of nonresponse to pharmacotherapy in panic disorder:a review. Depress Anxiety 14:112-122, 2001
PubMed
P.152 掲載の参考文献
1) Kaplan A, Hollander E:A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 54:1111-1118, 2003
PubMed
2) 吉田卓史, 多賀千明, 福居顯二:強迫性障害の長期治療計画. 臨床精神薬理 3:27-33, 2000
 
3) Dell' Osso B, Allen A, Hollander E:Fluvoxamine:a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 6:2727-2740, 2005
PubMed
4) 吉田卓史, 多賀千明, 福居顯二:SSRIの臨床-強迫性障害. 脳21 3:84-88, 2000
 
5) Greist JH, Bandelow B, Hollander E et al:WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 8 (suppl 1):S7-S16, 2003
 
6) Hollander E, Allen A, Steiner M et al:Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Clin Psychiatry 64:1113-1121, 2003
PubMed
7) 上島国利, 村崎光邦, 浅井昌弘ほか:塩酸パロキセチン (パキシル) の強迫性障害に対する臨床評価-プラセボを対照とした二重盲検比較試験. 薬理と治療 32:577-591, 2004
Medical*Online
8) Kronig MH, Apter J, Asnis G et al:Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19:172-176, 1999
 
9) 中前貴, 吉田卓史, 福居顯二:SSRI SNRIの強迫性障害の適応. 臨床精神医学 34:1381-1387, 2005
 
10) Ninan PT, Koran LM, Kiev A et al:High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder:a multicenter double-blind trial. J Clin Psychiatry 67:15-22, 2006
 
11) Tollefson GD, Rampey Jr AH, Potvin JH et al:A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51:559-567, 1994.
 
12) Montgomery SA, Kasper S, Stein DJ et al:Citalopram 20mg, 40mg and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:75-86, 2001
 
13) Geller DA, Biederman J, Stewart SE et al:Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 160:1919-1928, 2003
PubMed
14) Denys D, van Megen HJ, van der Wee N et al:A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65:37-43, 2004
PubMed
15) Schruers K, Koning K, Luermans J et al:Obsessive-compulsive disorder:a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261-271, 2005
PubMed
16) 吉田卓史, 秋篠雄哉, 松本良平 ほか:Quetiapineの付加療法が奏功した衝動性が強かった強迫性障害の1例. 強迫性障害の研究 6:105-109, 2005
 
17) 吉田卓史, 秋篠雄哉, 松本良平 ほか:セロトニン再取り込み阻害薬にperospironeの付加投与が有効であった巻き込み型強迫性障害の5症例. 臨床精神薬理 8:449-456 2005
 
P.160 掲載の参考文献
1) Effective Treatment for PTSD:Practice Guidelines from the International Society for Traumatic Stress Studies, ed. by Foa EB, Keane TM, Friedman MJ, The Guilford Press, New York, 2000 (飛鳥井望, 西園文, 石井朝子訳:PTSD治療ガイドライン:エビデンスに基づいた治療戦略, 金剛出版, 東京, 2005)
 
2) Ursano RJ, Bell C, Eth S et al:Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 161:3-31, 2004
PubMed
3) National Institute for Clinical Excellence:Post-traumatic stress disorder (PTSD):the management of PTSD in adults and children in primary and secondary care, London, UK, 2005 (http://www.nice.org.uk/page.aspx?o=CGO26 よりダウンロード可能)
 
4) van der Kolk BA, Dryfuss D, Michaels M et al:Fluoxetine in post-traumatic stress disorder. J Clin Psychiatry 55:517-522, 1994
 
5) Connor KM, Sutherland SM, TUpler LA et al:Fluoxetine in post-traumatic stress disorder:randomized, double-blind study. Br J Psychiatry 175:17-22, 1999
PubMed
6) Brady K, Pearlstein T, Asnis GM et al:Efficacy and safety of sertraline treatment of posttraumatic stress disorder:a randomized controlled trial. JAMA 283:1837-1844, 2000
PubMed
7) Davidson JR, Rothbaum BO, van der Kolk BA et al:Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58:485-492, 2001
PubMed
8) Marshall RD, Beebe KL, Oldham M et al:Efficacy and safety of paroxetine treatment for chronic PTSD:a fixed-dose, placebo-controlled study. Am J Psychiatry 158:1982-1988, 2001
PubMed
9) Tucker P, Zaninelli R, Yehuda R et al:Paroxetine in the treatment of chronic posttraumatic stress disorder:results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:860-868, 2001
 
10) De Boer M, Op den Velde W, Falger PJ et al:Fluvoxamine treatment for chronic PTSD:a pilot study. Psychother Psychosom 57:158-163, 1992
PubMed
11) Marmar CR, Schoenfeld F, Weiss DS et al:Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 57 (suppl 8):S66-S72, 1996
 
12) Davidson JR, Weisler RH, Malik M et al:Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol 18:93-95, 1998
PubMed
13) Davidson JR, Pearlstein T, Londborg P et al:Efficacy of sertraline in preventing relapse of posttraumatic stress disorder:results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158:1974-1981, 2001
 
14) Davidson JR, Landerman LR, Farfel GM et al:Characterizing the effects of sertraline in posttraumatic stress disorder. Psychol Med 32:661-670, 2002
PubMed
15) Ballenger JC:Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 65:1696-1707, 2004
PubMed
16) Stein MB, Kline NA, Matloff JL:Adjunctive olanzapine for SSRI-resistant combat-related PTSD:a double-blind, placebo-controlled study. Am J Psychiatry 159:1777-1779, 2002
PubMed
P.166 掲載の参考文献
1) 高橋三郎, 大野裕, 染矢俊幸 訳:DSM-IV-TR 精神疾患の分類と診断の手引き, 医学書院, 東京, 2002, pp.189-191
 
2) 塩入俊樹:抗うつ薬. 心療内科 6:453-458 2002
 
3) Maizels M McCarberg B:Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 71:483-490 2005
PubMed
4) Sack K:The pain that never heals:diagnosing and managing patients with fibromyalgia. Adv Stud Med 4:401-408, 2004
 
5) Fishbain D:Evidence-based data on pain relief with antidepressants. Ann Med 32:305-316, 2000
PubMed
6) Briley M:Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 19(suppl):S21-S25, 2004
 
7) Coluzzi F, Mattia C:Mechanism-based treatment in chronic neuropathic pain:the role of antidepressants. Curr Pharm Des 11:2945-2960, 2005
PubMed
8) 佐伯茂:III治療編-薬物治療-B. 鎮痛補助薬, 痛み, 花岡一雄 編, 朝倉書店, 東京, 2003, pp.274-285
 
9) Verma S, Gallagher RM:The psychopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr Pain Headache Rep 6:30-39, 2002
PubMed
10) Duman EN, Kesim M, Kadioglu MP et al:Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 94:161-165, 2004
 
11) Manna V, Bolino F, Di Cicco L:Chronic tension-type headache, mood depression and serotonin:therapeutic effects of fluvoxamine and mianserine. Headache 34:44-49, 1994
PubMed
12) Bank J:A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 34:476-478, 1994
 
13) Foster CA, Bafaloukos J:Paroxetine in the treatment of chronic daily headache. Headache 34:587-589, 1994
PubMed
14) Lynch ME:Antidepressants as analgesics:a review of randomized controlled trials. J Psychiatry Neurosci 26:30-36, 2001
PubMed
15) Miller LJ, Kubes KL:Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 36:707-712, 2002
PubMed
16) Varia I, Logue E, O'connor C et al:Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 140:367-372, 2000
PubMed
17) Lee RA, West RM, Wilson JD:The response tosertraline in men with chronic pelvic pain syndrome. Sex Transm Infect 81:147-149, 2005
PubMed
18) 町田英世, 中井吉英:慢性疼痛の治療-心理療法-. 精神科治療学 15:281-287, 2000
 
19) Noyes R Jr, Happel RL, Muller BA et al:Fluvoxamine for somatoform disorders:an open trial. Gen Hosp Psychiatry 20:339-344, 1998
PubMed
20) Oosterbaan DB, van Balkom AJ, van Boeijen CA et al:An open study of paroxetine in hypochondiasis. Prog Neuropsychopharmacol Biol Psychiatry 25:1023-1033, 2001
PubMed
21) Black K, Shea C, Dursun S et al:Selective serotonin reuptake inhibitor discontinuation syndrome:proposed diagnostic criteria. J Psychiarty Neurosci 25:255-261, 2000
 
22) 上島国利, 樋口輝彦, 神庭重信:「うつ病の薬物療法についての考え方」実態調査結果とそれを受けての提言. 日本醫事新報 4262:18-24 2005
Medical*Online
23) Verma S, Gallagher RM:The psychopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr Pain Headache Rep 6:30-39, 2002
PubMed
P.174 掲載の参考文献
1) 千田要一, 久保千春:各診療科での抗不安薬治療の実際-症例提示-. Modern Physician 24:1055-1058, 2004
 
2) Hasler G, Gergen PJ, Kleinbaum DG et al:Asthma and panic in young adults. Am J Respir Crit Care Med 171:1224-1230, 2005
PubMed
3) 永田頒史, 十川博, 西間三馨ほか:心身症診断.治療ガイドライン2006. 小牧元, 久保千春, 福土審 編, 協和企画, 東京, 2006, pp.64-71
 
4) 千田要一, 久保千春:心療内科の治療法. 現代心療内科学, 久保千春, 中井吉英, 野添新一 編, 永井書店, 大阪, 2003, pp.301-316
 
5) 千田要一, 久保千春:SSRI. 内科 92:654-658, 2003
 
6) 千田要一, 久保千春:抑うつを伴う気管支喘息にFluvoxamineを使用した1例. フルボキサミン症例集 (九州版). 2006, pp.15-16
 
P.179 掲載の参考文献
1) Drossman DA:The functional gastrointestinal disorders and the Rome III process. Gastroenterolog 130:1377-1390, 2006
 
2) Longstreth GF, Thompson WG Chey WD et al:Functional bowel disorders. Gastroenterology 130:1480-1491, 2006
PubMed
3) Drossman DA, Richter JE, Talley NJ et al:The Functional Gastrointestinal Disorders. Little Brown, Boston, 1994, pp.1-174
 
4) 福土審, 金澤素, 篠崎雅江ほか:過敏性腸症候群. 心身症診断治療ガイドライン2006, 小牧元, 久保千春, 福土審 編集, 協和企画, 東京, 2006, pp.11-40
 
5) 正宗研, 三輪剛, 福富久之ほか:過敏性腸症候群に対するポリカルボフィルカルシウム (HSR-237) の第m相試験. 薬理と治療 26(suppl):S967-S996, 1998
 
6) Poynard T, Naveau S, Chaput JC:Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 8:499-510, 1994
PubMed
7) 遠藤由香, 吉澤正彦, 福土審ほか:過敏性腸症候群におけるパニック障害. 心身医 40:339-346, 2000
Medical*Online
8) 吉澤正彦, 遠藤由香, 福土審ほか:パニック障害と過敏性腸症候群の関連-パニック障害からの検討. 心身医 40:283-289, 2000
Medical*Online
9) Drossman DA, Toner BB, Whitehead WE et al:Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125:19-31, 2003
 
10) Creed F, Fernandes L, Guthrie E et al:North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124:303-317, 2003
 
11) Prather CM, Camilleri M, Zinsmeister AR et al:Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118:463-468, 2000
PubMed
12) Lavo B, Stenstam M, Nielsen AL:Loperamide in treatment of irritable bowel syndrome--a double blind placebo controlled study. Scand J Gastroenterol 22 (suppl 130):S77-S80, 1987
 
13) Suzuki J, Yamauchi Y, Yamamoto H et al:Fasting therapy for psychosomatic disorders in Japan. Psychother Psychosom 31:307-314, 1979
PubMed
14) Kanazawa M, Fukudo S:Efficacy of fasting therapy for irritable bowel syndrome. Int J Behav Med 13:214-220, 2006
 
15) Heyman-Monnikes I, Arnold R, Florin I et al:The combination of medical treatment plus multi-component behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 95:981-994, 2000
 
16) Whorwell PJ, Prior A, Faragher EB:Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 2:1232-1234, 1984
PubMed
17) Talley NJ, Owen BK, Boyce P et al:Psychological treatments for irritable bowel syndrome:a critique of controlled treatment trials. Am Gastroenterol 91:277-283, 1996
PubMed
P.186 掲載の参考文献
1) 厚生省特定疾患調査研究事業 (重点). 特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班 (主任研究者:大野良之):平成10年度研究業績集, 1998
 
2) 高橋三郎, 大野裕, 染矢俊幸訳:DSM-IV-TR 精神疾患の分類と診断の手引. 医学書院, 東京, 2002
 
3) Ferguson CP, La Via MC, Crossan PJ et al:Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 25:11-17, 1999
PubMed
4) Kaye WH, Nagata T, Weltzin TE et al:Double-blind placebo-controlled administration of fluoxetine in restricting-and restricting-purging-type anorexia nervosa. Biol Psychiatry 49:644-652, 2001
PubMed
5) Holtkamp K, Konrad K, Kaiser N et al:A retrospective study of SSRI treatment in adolescent anorexia nervosa:insufficient evidence for efficacy.J Psychiatr Res 39:303-310, 2005
 
6) Fassino S, Leombruni P, Daga G et al:Efficacy of citalopram in anorexia nervosa:a pilot study. Eur Neuropsychopharmacol 12:453-459, 2002
PubMed
7) Ayuso-Gutierrez JL, Palazon M, Ayuso-Mateos JL:Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord 15:245-249, 1994
PubMed
8) Milano W, Siano C, Putrella C et al:Treatment of bulimia nervosa with fluvoxamine:a randomized controlled trial. Adv Ther 22:278-283, 2005
PubMed
9) Milano W, Capasso A De Rosa M et al:Treatment of binge eating disorder with sertraline:a randomized controlled trial (Eng). Eur Psychiatry 19(Suppl 1):226S, 2004
 
10) Milano W, Petrella C, Capasso A:Treatment of binge eating disorder with sertraline:a randomized controlled trial (Eng). Biomed Res 16:89-91, 2005
 
P.193 掲載の参考文献
1) 新福尚武:仮面うつ病-特に最近の問題点-. 心身医療 5:449-454, 1993
 
2) 融道男 中根充文 小見山実監訳:ICD-10 精神および行動の障害医学書院 東京 1993, p.175
 
3) 高橋三郎 花田耕一 藤縄昭訳:DSM-III 精神障害の分類と診断の手引 医学書院 東京, 1982
 
4) Tofler GH, Stone PH, Maclure M et al:Analysis of possible triggers of acute myocardial infarction (the MILIS Study). Am J Cardiol 66:22-27, 1990
PubMed
5) Myers A Dewar HA:Circumstances attending 100 sudden deaths from coronary artery disease with coroner's necropsies. Br Heart J 37:1133-1143, 1975
PubMed
6) Dunbar F:Emotions and Bodily Change. Columbia Univ. Press, New York, 1954
 
7) Friedman M, Rosenman RH:Association of specific overt pattern with blood and cardiovascular findings;blood cholesterol level, blood clotting time, incidence of arcus senilis, and coronary artery disease. JAMA 169:1286-1296, 1959
 
8) Brand RJ, Rosenman RH, Sholtz RI et al:Multi-variate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study. Circulation 53:348-355, 1976
 
9) Friedman M, Thoresen CE, Gill JJ et al:Alternation of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients:summary results of the recurrent coronary prevention project. Am Heart J 112:653-665, 1986
 
10) 前田聰 伊藤昭男 平山治雄 ほか虚血性心疾患発症後の簡易行動修正カウンセリングによるタイプAの治療. タイプA 5:25-31, 1994
 
11) Carney RM Blumenthal JA, Freedland KE et al:Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 66:466-474, 2004
PubMed
12) Cannon WB:Bodily Changes in Pain, Hunger, Fear and Rage. 2nd ed., Bradford, Boston, 1953
 
13) Alexander F:Psychosomatic Medicine (心身医学 末松弘行監訳 学樹書院 東京 1997)
 
P.200 掲載の参考文献
1) 堀川直史 山崎友子 佐川正夫 ほか糖尿病とうつ状態. うつ状態の頻度うつ状態と血糖コントロール及び糖尿病合併症との関連. 総合院精神医学 10:102-107, 1998
 
2) 任和子 北谷直美 松下勝代 ほか 2型糖尿病患者における心理社会的ストレサー及び抑うっ状態と血糖コントロールの関連. 心療内科 6:304-307, 2002
 
3) Robinson N, Fuller JH, Edmeades SP:Depression and diabetes. Diabet Med 5:268-274, 1988
PubMed
4) Wells KB, Golding JM, Burnam MA:Affective, substance use and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung conditions. Gen Hosp Psychiatry 11:320-327, 1989
 
5) Weyerer S, Hewer W, Pfeifer-Kurda M et al:Psychiatric disorders and diabetes--results from a community study J Psychosom Res 33:633-640, 1989
PubMed
6) Kovacs M, Obrosky DS, Goldston D et al:Major depressive disorder in youths with IDDM. A controlled prospective study of course and outcome. Diabetes Care 20:45-51, 1997
PubMed
7) Lustman PJ, Griffith LS, Clouse RE:Depression in adults with diabetes. Results of 5-yr follow-up study. Diabetes Care 11:605-612, 1988
PubMed
8) Eaton WW, Armenian H, Gallo J et al:Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 19:1097-1102, 1996
 
9) Kawakami N Takatsuka N, Shimizu H et al:Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 22:1071-1076, 1999
PubMed
10) Everson-Rose SA, Meyer PM, Powell LH et al:Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27:2856-2862, 2004
PubMed
11) Arroyo C, Hu FB, Ryan LM et al:Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care 27:129-133, 2004
PubMed
12) Lin EH, Katon W, Von Korff M et al:Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 27:2154-2160, 2004
PubMed
13) Nemeroff CB, Widerlov E, Bissette G et al:Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344, 1984
PubMed
14) Arana GW, Baldessarini RJ, Ornsteen M:The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 42:1193-1204, 1985
PubMed
15) Banki CM, Karmacsi L, Bissette G et al:CSF corticotropin-releasing hormone and somatostatin in major depression:response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2:107-113, 1992
PubMed
16) Kiraly SJ, Ancill RJ, Dimitrova G:The relationship of endogenous cortisol to psychiatric disorder:a review. Can J Psychiatry 42:415-420, 1997
PubMed
17) Wyatt RJ, Portnoy B, Kupfer DJ et al:Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 24:65-70, 1971
PubMed
18) Horacek J Kuzmiakova M, Hoschl C et al:The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 24:785-797, 1999
PubMed
19) Polonsky WH, Anderson BJ, Lohrer PA et al:Assessment of diabetes-related distress. Diabetes Care 18:754-760, 1995
PubMed
20) Okamura F, Tashiro A Utumi A et al:Insulin resistance in patients with depression and its changes during the clinical course of depression:minimal model analysis. Metabolism 49:1255-1260, 2000
PubMed
21) Lustman PJ, Griffith LS, Clouse RE et al:Effects of nortriptyline on depression and glycemic control in diabetes:results of a double-blind, placebo-controlled trial. Psychosom Med 59:241-250, 1997
PubMed
22) Masaki T, Chiba S, Yasuda T et al:Involvementof hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 53:2250-2260, 2004
 
23) Lustman PJ, Freedland KE, Griffith LS et al:Fluoxetine for depression in diabetes:a randomized double-blind placebo-controlled trial. Diabetes Care 23:618-623, 2000
PubMed
24) Paile-Hyvarinen M, Wahlbeck K, Eriksson JG:Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine:a single-blind randomised placebo controlled trial. BMC Fam Pract, Epub 2003 May 14
 

Part4 / SSRIの投与法の実際

P.207 掲載の参考文献
1) 野村総一郎 抗うつ薬の多剤併用. 臨床精神薬理 5:863-867, 2002
 
2) Jick H, Dinan BJ, Hunter JR et al:Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 3:182-185, 1983
PubMed
3) McCombs JS, Nichol MB, Stimmel GL et al:The cost of antidepressant drug therapy failure:a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 51 (suppl):S60-S69;discussion 70-71, 1990
 
4) Donoghue JM, Tylee A:The treatment of depression:prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 168:164-168, 1996
PubMed
5) Kupfr DJ:Long-term treatment of depression. J Clin Psychiatry 52 (suppl):S28-S34, 1991
 
6) Deppression in Primary Care:Detection, Diagnosis, and Treatment:AHCPR publication No. 93-0552, 1993
 
7) Anderson IM, Nutt DJ, Deakin JF:Evidence-based guidelines for treating depressive disorders with antidepressants:a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14:3-20, 2000
PubMed
8) Campbell S, Marriott M, Nahmias C et al:Lower hippocampal volume in patients suffering from depression:a meta-analysis. Am J Psychiatry 161:598-607, 2004
PubMed
9) Steffens DC, Byrum CE, McQuoid DR et al:Hippocampal volume in geriatric depression. Biol Psychiatry 48:301-309, 2000
PubMed
10) Bremner JD, Narayan M, Anderson ER et al:Hippocampal volume reduction in major depression. Am J Psychiatry 157:115-118, 2000
PubMed
11) Sheline YI, Gado MH, Kraemer HC:Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516-1518, 2003
PubMed
12) Quitkin FM, McGrath PJ, Stewart JW et al:Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 53:785-792, 1996
PubMed
13) Nierenberg AA:Treatment choice after one antidepressant fails:a survey of northeastern psychiatrists. J Clin Psychiatry 52:383-385, 1991
 
14) Thase ME, Sullivan LR:Relapse and recurrense of depression:a practical approach for prevention. CNS Drugs 4:261-277, 1995
 
15) Frank E, Kupfer DJ, Perel JM et al:Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099, 1990
PubMed
16) American Psychiatric Association:Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157:1-45, 2000
PubMed
17) Anderson IM, Nutt DJ, Deakin JF:Evidence-based guidelines for treating depressive disorders with antidepressants:a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology J Psychopharmacol 14:3-20, 2000
PubMed
18) 青葉安里 元山英勝 影山聡 ほかうつ病又はうつ状態の患者を対象とした塩酸パロキセチン水和物の健康関連QOLの検討-塩酸パロキセチン水和物の open-label 多施設共同試験-. 臨床精神薬理 7:1169-1192, 2004
 
19) 青葉安里 元山英勝 影山聡 ほか塩酸パロキセチン水和物のうつ病又はうつ状態の患者を対象とした市販後臨床試験-塩酸イミプラミンを対照とした二重盲検比較試験臨床精神薬理 7:831-853, 2004
 
20) 斉藤正己 木下利彦 渡辺昌祐 選択的セロトニン再取り込み阻害薬塩酸パロキセチンのうつ病およびうつ状態に対する長期投与試験. 薬理と治療 28:211-223, 2000
 
21) Franchini L, Gasperini M, Perez J et al:ose-response efficacy of paroxetine in preventing depressive recurrences:a randomized, double-blind study. J Clin. Psychiatry 59:229-232, 1998
 
22) 村崎光邦 森温理 三浦貞則ほか選択的セロトニン再取り込み阻害薬 SME3110 (fluvoxamine maleate) のうつ病 うつ状態に対する臨床評価-塩酸アミトリプチリンとの二重盲検比較試験. 臨床医薬 14:951-980, 1998
 
23) Mackay FJ, Dunn NR, Freemantle SN et al:A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 6:235-246, 1997
PubMed
24) ルボクス錠25・50特別調査-長期使用に関する特別調査-うつ病・うつ状態に関する結果報告書 (DIRO50009), 2005.10.28, アステラス製薬
 
25) Ware MR:Fluvoxamine:a review of the controlled trials in depression. J Clin Psychiatry 58 (suppl 5):S15-S23, 1997
 
26) Walczak DD, Apter JT, Halikas JA et al:The oral dose-effect relationship for fluvoxamine:a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 8:139-151, 1996
PubMed
27) Morishita S, Arita S:Suitable dose and duration of fluvoxamine administration to treat depression. Psychiatry Clin Neurosci 57:177-181, 2003
PubMed
28) Terra JL, Montgomery SA:Fluvoxamine prevents recurrence of depression:results of a long-term double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55-62, 1998
PubMed
29) Franchini L, Gasperini M, Perez J et al:A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58:104-107, 1997
PubMed
30) Preskorn SH, Lane RM:Sertraline 50 mg daily:the optimal dose in the treatment of depression. Int Clin Psychopharmacol 10:129-141, 1995
PubMed
31) Fabre LR, Amin AM, Claghorn JL et al:Sertra line safety and efficacy in major depression:a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38:592-602, 1995
 
32) Doogan DP, Langdon CJ:A double-blind comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 9:95-100, 1994
PubMed
33) Moon CAL, Jago W, Wood K et al:A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J Psychopharmacol 8:171-176, 1994
 
34) 村崎光邦 上島国利 山下格 ほか選択的セロトニン再取り込み阻害薬塩酸セルトラリンのうつ病およびうつ状態に対する臨床評価-塩酸イミプラミンを対照薬とした用量設定試験 神経精神薬理 19:505-527, 1997
 
35) Lepine JP, Caillard V, Bisserbe JC et al:A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161:836-842, 2004
PubMed
36) Keller MB, Kocsis JH, Thase ME et al:Maintenance phase efficacy of sertraline for chronic depression:a randomized controlled trial. JAMA 280:1665-1672, 1998
PubMed
37) 大森哲郎 向精神薬の併用 有効な場合と有害な場合. 臨床精神医学 30:1071-1076, 2001
Medical*Online
P.213 掲載の参考文献
1) Montgomery SA, Kasper S:Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants:a meta-analysis. Int Clin Psychopharmacol 9(suppl 4):S33-S40, 1995
 
2) Hotopf M, Hardy R, Lewis G:Discontinuation rates of SSRI and tricyclic antidepressants:a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170:120-127, 1997
 
3) Thompson C, Peveler RC, Stephenson D et al:Compliance with antidepressant medication in the treatment of major depressive disorder in primary care:a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 157:338-343, 2000
 
4) Meijer WE, Bouvy ML, Heerdink ER et al:Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 179:519-522, 2001
PubMed
5) Michelson D, Fava M, Amsterdam J et al:Interruption of selective serotonin reuptake inhibitor treatment Double-blind, placebo-controlled trial. Br J Psychiatry 176:363-368, 2000
PubMed
6) Bull SA, Hu XH, Hunkeler EM et al:Discontinuation of use and switching of antidepressants:influence of patient-physician communication. JAMA 288:1403-1409, 2002
PubMed
P.220 掲載の参考文献
1) Paykel ES:Historical overview of outcome of depression. Br J Psychiatry Suppl:6-8, 1994
PubMed
2) Demyttenaere K, Bruffaerts R, Posada-Villa J et al:Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 291:2581-2590, 2004
PubMed
3) Stahl SM:Mergers and acquisitions among psychotropics:antidepressant takeover of anxiety may now be complete. J Clin Psychiatry 60:282-283, 1999
PubMed
4) Potter WZ, Manji HK, Rudorfer MV:Tricyclics and tetracyclics. In:Essentials of Clinical Psychopharmacology. ed. by Schatzberg A, Nemer-off CB, American Psychiatric Publishing, Washington, DC, 2001, pp.5-26
 
5) Fernstrom MH, Krowinski RL, Kupfer DJ:Chronic imipramine treatment and weight gain. Psychiatry Res 17:269-273, 1986
PubMed
6) Geddes JR, Carney SM, Davies C et al:Relapse prevention with antidepressant drug treatment in depressive disorders:a systematic review. Lancet 361:653-661, 2003
PubMed
7) Olfson M, Marcus SC, Tedeschi M et al:Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 163:101-108, 2006
PubMed
8) Campbell-Sills L, Stein MB:Guideline watch:Practice Guideline for the Treatment of Patients with Panic Disorder. American Psychiatric Association, Washington, DC, 2006
 
9) Bruce SE, Yonkers KA, Otto MW et al:Infuence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder:a 12-year prospective study. Am J Psychiatry 162:1179-1187, 2005
 
10) Rapaport MH, Wolkow R, Rubin A et al:Sertraline treatment of panic disorder:results of a long-term study. Acta Psychiatr Scand 104:289-298, 2001
PubMed
11) Koran LM, Hackett E, Rubin A et al:Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159:88-95, 2002
 
12) Hollander E, Allen A, Steiner M et al:Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121, 2003
PubMed
13) Stocchi F, Nordera G, Jokinen RH et al:Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258, 2003
 
14) 永田利彦 社会不安障害 社会不安スペクトラムの治療. 精神神経学雑誌 108:766-771, 2006
 
15) Walker JR, Van Ameringen MA, Swinson R et al:Prevention of relapse in generalized social phobia results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636-644, 2000
PubMed
16) Lader M, Stender K, Burger V et al:Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder:randomised, double-blind, placebo-controlled fixed-dose study. Depress Anxiety 19:241-248, 2004
 
17) Montgomery SA, Nil R, Durr-Pal N et al:A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278, 2005
PubMed
18) Wagner KD, Ambrosini P, Rynn M et al:Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder:two randomized controlled trials. JAMA 290:1033-1041, 2003
PubMed
19) Clark DB, Birmaher B, Axelson D et al:Fluoxetine for the treatment of childhood anxiety disorders:open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44:1263-1270, 2005
 
20) Rynn M, Wagner KD, Donnelly C et al:Longterm sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 16:103-116, 2006
PubMed
21) Fava M ,Judge R, Hoog SL et al:Fluoxetine versus sertraline and paroxetine in major depressive disorder:changes in weight with longterm treatment. J Clin Psychiatry 61:863-867, 2000
PubMed
22) Vasile RG, Bruce SE, Goisman RM et al:Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 22:59-67, 2005
PubMed
P.225 掲載の参考文献
1) 田所千代子 衛藤暁美 加藤高裕ほか Fluvoxamineの漸減中止によりSSRI離脱症候群を呈したうつ病の1例. 精神医学 43:547-549, 2001
 
2) 杉原徳郎 井上雄一 Paroxetineの退薬症候と考えられるインフルエンザ様症状を呈した2症例. 精神科治療学 18:221-225 2003
 
3) Black K, Shea C, Dursun S et al:Selective serotonin reuptake inhibitor discontinuation syndrome:proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261, 2000
PubMed
4) Haddad P:The SSRI discontinuation syndrome. J Psychopharmacol 12:305-313, 1998
PubMed
5) 竹内賢 星野研洋 鈴木喜明ほか SSRI の中止後発現症状の実態調査. 新薬と臨床 53:37-44, 2004
 
6) Coupland NJ, Bell CJ, Potokar JP:Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16:356-362, 1996
PubMed
7) Tamam L, Ozpoyraz N:Selective serotonin reuptake inhibitor discontinuation syndrome. Adv Ther 19:17-26, 2002
 
8) Perahia DG, Kajdasz DK Desaiah D et al:Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 89:207-212, 2005
PubMed
9) Schatzberg AF Blier P, Delgado PL et al:Antidepressant discontinuation syndrome:consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67 (supple 4):S27-S 30, 2006
 
P.229 掲載の参考文献
1) American Psychiatric Association:Practice guideline for major depressive disorder in adults. Am J Psychiatry 150 (suppl 4):S1-S26, 1993
 
2) American Psychiatric Association:Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (suppl 4):S1-S45, 2000
 
3) NICE:Depression:Management of depression in primary and secondary care. National Institute for Clinical Excellence, London, 2004
 
4) Clinical Practice Guideline Number 5:Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, MD, US Dept Health Human Services, Agency for Health Care Policy and Research, 1993. AHCPR publication 93-0551
 
5) Dobson KS:A meta-analysis of the efficacy of the cognitive therapy for depression. J Consult Clin Psychol 57:414-419, 1989
PubMed
6) Gloaguen V, Cottraux J, Cucherat M et al:A meta-analysis of the effects of cognitive therapy in depressed people. J Affect Disord 49:59-72, 1998
 
7) Blackburn IM Moore RG:Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 171:328-334, 1997
PubMed
8) Fava GA, Grandi S, Zielezny M et al Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 151:1295-1299, 1994
PubMed
9) Elkin I, Shea MT, Watkins JT et al:National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 46:971-982, 1989
PubMed
10) Jarrett RB, Rush AJ:Short-term psychotherapy of depressive disorders current status and future directions. Psychiatry 57:115-132, 1994
PubMed
11) Shea MT, Pilkonis PA, Beckham E et al Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 147:711-718, 1990
PubMed
12) Schulberg HC, Block MR Madonia MJ et al Treating major depression in primary care practice:eight-month clinical outcomes. Arch Gen Psychiatry 53:913-919, 1996
PubMed
13) Barber JB, Muenz LR:The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy:empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol 64:951-958, 1996
 
14) Hollon SD Jarrett RB, Nierenberg AA et al Psychotherapy and medication in the treatment of adult and geriatric depression:which monotherapy or combined treatment? J Clin Psychiatry 66:455-468, 2005
PubMed
15) Blackburn IM, Bishop S, Glen AI et al:The efficacy of cognitive therapy in depression:a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 139:181-189, 1981
PubMed
16) Murphy GE Simons AD, Wetzel RD et al:Cognitive therapy and pharmacotherapy singly and together, in the treatment of depression. Arch Gen Psychiatry 41:33-41, 1984
PubMed
17) Hollon SD, DeRubeis RJ, Evans MD et al:Cognitive therapy and pharmacotherapy for depression:singly and in combination. Arch Gen Psychiatry 49:774-781, 1992
PubMed
18) Keller MB, McCullough JP, Klein DN et al:A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462-1470, 2000
PubMed
19) Friedman MA, Detweiler-Bedell JB, Leventhal HE et al:Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clin Psychol Sci Prac 11:47-68, 2004
 
20) Pampallona S, Bollini P, Tibaldi G et al:Combined pharmacotherapy and psychological treatment for depression:a systematic review. Arch Gen Psychiatry 61:714-719, 2004
PubMed
21) Bellack AS, Hersen M, Himmelhoch J:Social skills training compared with pharmacotherapyand psychotherapy in the treatment of unipolar depression. Am J Psychiatry 138:1562-1567, 1981
 
22) Miller IW, Norman WH, Keitner GI:Cognitive-behavioral treatment of depressed inpatients six-and twelve-month follow-up. Am J Psychiatry 146:1274-1279, 1989
PubMed
23) Miller IW, Norman WH, Keitner GI:Cognitive-behavioural treatment of depressed inpatients. Behav Ther 20:25-47, 1989
 
24) Ravindran AV, Anisman H, Merali Z et al:Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy:clinical symptoms and functional impairments. Am J Psychiatry 156:1608-1617, 1999
PubMed
25) Blackburn IM, Moore RG:Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br Psychiatry 171:328-334, 1997
PubMed
26) Scott C, Tacchi MJ, Jones R et al:Acute and one-year outcome of a randomized controlled trial of brief cognitive therapy for major depressive disorder in primary care. Br Psychiatry 171:131-134, 1997
PubMed
27) Weissman M, Prusoff B, Di Mascio A et al:The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 136:555-558, 1979
 
28) Herceg-Baron RL, Prusoff BA, Weissman MM et al:Pharmacotherapy and psychotherapy in acutely depressed patients:a study of attrition patterns in a clinical trial. Compr Psychiatry 20:315-325, 1979
 
29) Mynors-Wallis LM, Gath DH, Day A et al:Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 320:26-30, 2000
PubMed
30) Friedman A:Interaction of drug therapy with marital therapy in depressed patients. Arch Gen Psychiatry 32:619-637, 1975
PubMed
31) Burnand Y, Andreoli A, Kolatte E et al:Psycho-dynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 53:585-589, 2002
 
32) Browne G, Steiner M, Roberts J et al:Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care:6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 68:317-330, 2002
PubMed
33) de Jonghe F, Kool S, van Aalst G et al:Combining Psychotherapy and antidepressants in the treatment of depression. J Affect Disord 64:217-229, 2001
PubMed
34) Hellerstein DJ, Little SA, Samstag LW et al:Adding group psychotherapy to medication treatment in dysthymia:a randomized prospective pilot study. J Psychother Pract Res 10:93-103, 2001
PubMed
35) Thase ME, Greenhouse JB, Frank E et al:Treatment of major depression with psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 54:1009-1015, 1997
PubMed
36) Bowers WA:Treatment of depressed inpatients:cognitive therapy plus medication, relaxation plus medication, and medication alone. Br J Psychiatry 156:73-78, 1990
PubMed
37) March J, Silva S Petrycki S et al:Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression:Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004
PubMed
38) Anderson IM, Tomenson BM:Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants:a meta-analysis. BMJ 310:1433-1438, 1995
PubMed
P.235 掲載の参考文献
1) Koyama E, Chiba K, Tani M et al:Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation:a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Ther 281:1199-1210, 1997
 
2) 澤田康文 薬物動態学と相互作用. 臨床精神薬 理ハンドブク 樋口輝彦 小山司 神庭重信 編 医学書院 東京 2003, pp. 34-52
 
3) Trivedi MH Using treatment algorithms to bring Patients to remission. J Clin Psychiatry 64 (suppl 2):S8-S13, 2003
 
4) Nelson JC, Mazure CM, Bowers MB Jr et al:A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307, 1991
PubMed
5) Taylor D:Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br Psychiatry 167:575-580, 1995
PubMed
6) Caccia S:Metabolism of the newer anti-depressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302, 1998
 
7) Rasmussen BB, Brosen K:Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143-154, 2000
PubMed
8) Spina E, Campo GM, Avenoso A et al:Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14:194-196, 1992
PubMed
9) Spina E, Pollicino AM, Avenoso A et al:Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243-246, 1993
PubMed
10) Vandel S, Bertschy G, Baumann P et al:Fluvoxamine and fluoxetine:interaction studies with amitriptyline clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353, 1995
PubMed
11) Albers LJ, Reist C, Helmeste D et al:Paroxetine shifts imipramine metabolism. Psychiatry Res 59:189-196, 1996
PubMed
12) Alderman J, Preskorn SH, Greenblatt DJ et al:Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291, 1997
PubMed
13) Hyttel J, Bogeso KP, Perregaard J et al:The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. 11Veural Transm Gen Sect 88:157-160, 1992
 
14) De Vane Liston HL, Markowitz JS:Clinical pharmacokinetics of sertraline. Clin Pharmacoleinet 41:1247-1266, 2002
PubMed
15) Preskorn SH, Alderman J, Chung M et al:Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Clin Psychopharmacol 14:90-98, 1994
 
16) Barros J, Asnis G:An interaction of sertraline and desipramine. Am J Psychiatry 150:1751, 1993
PubMed
17) 鶴田一壽 鶴井一幸 岡崎勝也 ほか 塩酸ミルナシプランのヒトP450を介する薬物相互作用の検討. 医薬品研究31:149-151, 2004
 
18) Fleishaker JC, Hulst LK:A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur Clin Pharmacol 46:35-39, 1994
PubMed
19) Carrillo JA, Dahl ML, Svensson JO et al:Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1 A2 activity. Clin Pharmacol Ther 60:183-190, 1996
 
20) Daniel DG, Randolph C, Jaskiw G et al:Coadministration of fluvoxamine increases serum concentrations of haloperidol. Clin Psychopharmacol 14:340-343, 1994
PubMed
21) Hiemke C, Weigmann H, Hartter S et al:Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281, 1994
PubMed
22) Jong J, Hoogenboom B, Troostwijk LD et al:Interaction of olanzapine with fluvoxamine. Psychopharmacol 155:219-220, 2001
 
23) Ozdemir V, Naranjo CA, Herrmann N et al:Paroxetine potentiates the central nervous system side effects of perphenazine contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 62:334-347, 1997
PubMed
24) Spina E, Avenoso A, Faccioca G et al:Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23:223-227, 2001
 
P.241 掲載の参考文献
1) Bourin M:Use of paroxetine for the treatment of depression and anxiety disorders in the elderly a review. Hum Psychopharmacol 18:185-190, 2003
PubMed
2) Budman CL, Sherling M, Brunn RD:Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 34:263-264, 1995
 
3) Guillibert E, Pelicier Y, Archambault JC et al:A double blind multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 350:132-134, 1989
PubMed
4) Reynolds CF 3rd, Dew MA, Pollock BG et al:Maintenance treatment of major depression in old age. N Engl Med 354:1130-1138, 2006
PubMed
5) Kirby D, Ames D:Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int Geriatr Psychiatry 16:484-493, 2001
PubMed
6) Roose SP, Sackeim HA, Krishnan KR et al:Anti-depressant pharmacotherapy in the treatment of depression in the very old:a randomized placebo-controlled trial. Am J Psychiatry 161:2050-2059, 2004
 
7) Dunbar GC:Paroxetine in the elderly:a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 51:137-144, 1995
PubMed
8) Juurlink DN, Mamdani MM Kopp A et al:The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813-821, 2006
PubMed
9) 正木慶大 西川隆 池尻義隆 ほか Pick病の反復行動に対する選択的セロトニン再取り込み阻害剤 (SSRI) の効果. 分子精神医学 1:212-213, 2001
 

Part5 / 治療上の注意点と安全性

P.251 掲載の参考文献
1) 野村健介 渡邊衡一郎 新規抗うつ薬のリスクとベネフィト. 臨床精神薬理 8:1687-1695, 2005
 
2) Isbister GK, Bowe SJ, Dawson A et al:Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Toxicol Clin Toxicol 42:277-285, 2004
PubMed
3) 辻敬一郎 田島治 抗うつ薬によるactivation syndrome. 臨床精神薬理 8 1697-1704, 2005
 
4) Barnhart WJ, Makela EH, Latocha MJ:SSRI-induced apathy syndrome:a clinical review. J Pschiatr Pract 10:196-199, 2004
PubMed
5) Gentile S:The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28:137-152, 2005
PubMed
6) Sanz EJ, De-las-Cuevas C, Kiuru A et al:Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome a database analysis. Lancet 365:482-487, 2005
PubMed
7) Moses-Kolko EL, Bogen D, Perel J et al:Neonatal signs after late in utero exposure to serotonin reuptake inhibitors literature review and implications for clinical applications. JAMA 293:2372-2383, 2005
PubMed
8) Chambers CD, Hernandez-Diaz S, Van Marter LJ et al:Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl Med 354:579-587, 2006
PubMed
9) Sternbach H:The serotonin syndrome. Am J Psychiatry 148:705-713, 1991
PubMed
10) Spina E, Scordo MG, D'Arrigo C:Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538, 2003
PubMed
11) 吉田郁子 川西千秋 平安良雄 薬物相互作用への配慮抗うつ薬の薬物動態と相互作用. 治療87:575-580, 2005
 
P.257 掲載の参考文献
1) Young JL, Zonana HV, Shepler L:Medication noncompliance in schizophrenia codification and update. Bull Am Acad Psychiatry Law 14:105-122, 1986
PubMed
2) Haddad PM:Antidepressant discontinuation syndromes. Clinical relevance prevention and management. Drug Saf 24:183-197, 2001
 
3) Lejoyeux M, Ades J:Antidepressants discontinuation:a review of the literature. Clin Psychiatry 58:11-16, 1997
PubMed
4) Price JS, Waller PC, Wood SM et al:A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br Clin Pharmacol 42:757-763, 1996
PubMed
5) Rosenbaum JE, Zajecka J:Clinical management of antidepressant discontinuation. J CIin Psychiatry 58:37-40, 1997
 
6) Benazzi F:Nefazodone withdrawal symptoms. Can J Psychiatry 43:194-195, 1998
PubMed
7) Fava M:Mulroy R:Alpert J et al:Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 154:1760-1762, 1997
PubMed
8) MacCall C, Callender J:Mirtazapine withdrawal causing hypomania. Br J Psychiatry 175:390, 1999
PubMed
9) Perahia DG, Kajdasz DK, Desaiah D et al:Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Affect Disord 89:207-212, 2005
PubMed
10) 寺尾岳 抗うつ薬の離脱症状 SSRIsを中心に. 臨床精神薬理 7 793-799, 2004
 
11) Barr LC, Goodman WK, Price LH:Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 151:289, 1994
PubMed
12) Keuthen NJ, Cyr P, Ricciardi JA et al:Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 14:206-207, 1994
PubMed
13) Oehrberg S, Christiansen PE, Behnke K et al:Paroxetine in the treatment of panic disorder. A randomized double-blind placebo-controlled study. Br J Psychiatry 167:374-379, 1995
PubMed
14) Rosenbaum JE, Fava M, Hoog SL et al:Selective reuptake inhibitor discontinuation syndrome a randomized clinical trial. Biol Psychiatry 44:77-87, 1998
 
15) Black K, Shea C, Dursun S et al:Selective serotonin reuptake inhibitor discontinuation syndrome proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261, 2000
PubMed
16) Dilsaver SC, Feinberg M, Greden JF:Antidepressant withdrawal syndromes treated with anti-cholinergic agents. Am J Psychiatry 140:249-251, 1983
PubMed
17) Dilsaver SC, Greden JF:Antidepressant withdrawal phenomena. Biol Psychiatry 19:237-256, 1984
 
18) Lejoyeux M, Ades J, Mourad I et al:Antidepressant withdrawal syndrome recognition prevention and management. CNS Drugs 5:278-292, 1996
 
19) Dilsaver SC, Greden JE, Snider RM:Antidepressant withdrawal syndromes phenomenology and physiopathology. Int Clin Psychopharmacol 2:1-19, 1987
 
20) Charney DS, Heninger GR, Sternberg DE et al:Abrupt discontinuation of tricyclic antidepressant drugs:evidence for noradrenergic hyperactivity. Br J Psychiatry 141:377-386, 1982
PubMed
21) Coupland NJ, Bell CJ, Potokar JP:Serotonin reuptake inhibitor withdrawal. Clin Psychopharmacol 16:356-363, 1996
PubMed
22) Goodwin GM:How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 57:9-13, 1996
PubMed
23) Lane RM:Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). Serotonin Res 3:75-83, 1996
 
24) Zajecka J, Tracy KA, Mitchell S:Discontinuation symptoms after treatment with serotonin reuptake inhibitors:a literature review. J Clin Psychiatry 58:291-297, 1997
PubMed
25) Kaufman MJ, Henry ME, Frederick B et al:Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostra anterior cingulated choline metabolite decrease:a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 54:534-539, 2003
 
26) Michelson D, Amsterdam J, Apter J et al:Hormonal markers of stress response following interpretation of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 25:169-177, 2000
 
27) Young AH, Currie A, Ashton CH:Antidepressant withdrawal syndrome. Br J Psychiatry 170:288, 1997
PubMed
28) Michelson D, Fava M, Amsterdam J et al:Interruption of selective serotonin reuptake inhibitor treatment. Br Psychiatry 176:363-368, 2000
PubMed
29) van Geffen EC, Hugtenburg JG, Heerdink ER et al:Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice tapering versus abrupt discontinuation. Eur J Pharmacol 61:303-307, 2005
 
30) Pacheco L Malo P, Aragues E et al:More cases of paroxetine withdrawal syndrome. Br J Psychiatry 176:363-368, 2000
 
31) Benazzi F:SSRI discontinuation syndrome treated with fluoxetine. Int Geriatr Psychiatry 13:421-422, 1998
PubMed
32) Costei AM, Kozer E, Ho T et al:Perinatal outcome following third trimester exposure toparoxetine. Arch Pediatr Adolesc Med 156:1129-1132, 2002
PubMed
33) Nordeng H, Lindemann R, Perminov KV et al:Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90:288-291, 2001
PubMed
34) Oberlander TE, Misri S, Fitzgerald CE et al:Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65:230-237, 2004
 
P.264 掲載の参考文献
1) 傳田健三:児童・青年期の気分障害に対する薬物療法. 児童青年精神医学とその近接領域 44:371-380, 2003
 
2) 傳田健三:わが国における子どものうつ病の現状. 臨床精神薬理 7:1567-1577, 2004
 
3) Teicher MH, Cole JO, Glod C:Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210, 1990
PubMed
4) 岡田俊:児童青年期の大うつ病性障害における抗うつ薬の適応-国内外の抗うつ薬使用の規制に関する問題-. 児童青年精神医学とその近接領域 46 166-178, 2005
 
5) 辻敬一郎, 田島治:抗うつ薬によるactivation syndrome. 臨床精神薬理 8:1697-1704, 2005
 
6) Pohl R, Yeragani VK, Balon R et al:The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49:100-104, 1988
PubMed
7) 野崎昭子, 稲田俊也:抗うつ薬の副作用とその 対策. うつ病診療ハンドブク 樋口輝彦 編 メディカルレビュー社 東京 2002 pp.178-196
 

Part6 / 将来展望

P.273 掲載の参考文献
1) 田島治:ベンゾジアゼピン系薬物の処方を再考する. 臨床精神医学 30:1065-1069, 2001
Medical*Online
2) 村崎光邦:わが国における向精神薬の現状と展望-21世紀を目指して-. 臨床精神薬理 4 3-27, 2001
 
3) 石郷岡純:SSRI-わが国におけるうつ病治療の最前線. 臨床精神薬理 8 533-551, 2005
 
4) The Royal College of Psychiatrists:CR59. Benzodiazepines:risks benefits or dependence A re-evaluation. Council Report CR 59 January 1997, London, 1997
 
5) 衛藤理砂, 岡島由佳, 平島奈津子 ほか:日本における境界性人格障害に対する薬物療法の現状調査 精神神経薬理学会, 2005
 
6) Valenstein M, Taylor KK, Austin K et al:Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 161:654-661, 2004
PubMed
7) 宮田久嗣 中山和彦 不安障害の薬物療法における適応外使用. 精神科治療学21:503-507, 2006
 
P.278 掲載の参考文献
1) Greenberg PE, Stiglin LE, Finkelstein SN et al:The economic burden of depression in 1990. J CIin Psychiatry 54:405-418, 1993
 
2) Greenberg PE, Kessler RC, Birnbaum HG et al:The economic burden of depression in the United States:how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475, 2003
PubMed
3) Thomas CM, Morris S:Cost of depression among adults in England in 2000. Br Psychiatry 183:514-519, 2003
PubMed
4) 湯尾高根, 山内慶太:医療経済学から見た新規抗うつ薬臨床精神薬理 5:715-723, 2003
 
5) 山内慶太:薬物療法の経済評価の基本的な考え方と留意点-精神医療の特質に即して-. 臨床精神薬理 6:837-843, 2003
 
6) Barrett B, Byford S, Knapp M:Evidence of cost-effective treatment for depression:a systematic review. J Affect Disord 84:2-13, 2005
 
7) Woods SW, Rizzo JA:Cost-effectiveness of anti-depressant treatment reassessed. Br J Psychiatry 170:257-263, 1997
 
8) Jonsson B, Bebbington PE:What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br Psychiatry 164:665-673 1994
PubMed
9) Baker CB, Johnsrud MT, Crismon ML et al:Quantative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 183:498-506, 2003
 
10) Simon GE, Von Korff M, Heiligenstein JH et al:Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275:1897-1902, 1996
PubMed
11) Simon GE, Heiligenstein J, Revicki D et al:Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Fam Med 8:319-325, 1999
 
12) Hosak L, Tuma L, Hanus H et al:Costs and outcomes of use of amitriptyline citalopram and fluoxetine in major depression exploratory study. Acta Med (Hradec Kralove) 43:133-137, 2000
 
13) Forder J, Kavanagh S, Fenyo A:A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 38 97-111, 1996
PubMed
14) 山内慶太:わが国の臨床試験の方法論の再検討-特に多施設試験と有用性の意義について-. 精神医学レビューNo. 25向精神薬の開発をめぐって 上島国利 編 ライフ・サイエンス社 東京 1997, pp. 92-102
 
15) 山内慶太:ICH-GCP下の臨床試験の問題点-公平性・透明性の観点から-. 臨床精神薬理 4:797-804, 2001
 
16) Brrigs A:Economic evaluation and clinical trial size matters the need for greater power in cost analyses poses an ethical dilemma. BMJ 321:2362-2363, 2000
 
P.283 掲載の参考文献
1) 小林清香, 堀川直史:高齢者におけるサイコエデュケーション. 老年精神医学 17:267-271, 2006
Medical*Online
2) 後藤雅博:心理教育の歴史と理論. 臨床精神医学 30:445-450 2001
Medical*Online
3) Shimodera S, Inoue S, Mino Y et al:Expressed emotion and psycho educational intervention for relatives of patients with schizophrenia:a randomized controlled study in Japan. Psychiatry Res 96:141-148, 2000
 
4) Mino Y, Shimodera S, Inoue S et al:Expressed emotion of families and the course of mood disorders a cohort study in Japan. Affect Disord 63:43-49, 2001
PubMed
5) 下寺信次,三野善央,井上新平:うつ病における薬物療法と心理教育. 臨床精神薬理 8:23-28, 2005
 
6) Hosaka T:A pilot study of a structured psychiatric intervention for Japanese women with breast cancer. Psychooncology 5:59-64, 1996
 
7) 保坂隆:がん患者への構造化された精神科的介入の有効性について. 精神医学 41:867-870, 1999
 
8) Hosaka T, Sugiyama Y, Hirai K et al:Effects of a modified group intervention with early-stage breast cancer patients. Gen Hosp Psychiatry 23:145-151, 2001
PubMed
9) 保坂隆, 藤富豊:患者夫婦への教育的介入. TECHNICAL TERM 緩和医療 下山直人, 向山雄人, 山脇成人 編集 先端医学社 2002, pp. 122-123
 
10) 藤田博一, 下寺信次, 井上新平:上手な家族心理教育. 精神科 8 385-390, 2006
 
P.289 掲載の参考文献
1) Adrien J:Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 6:341-351, 2002
PubMed
2) Buysse DJ, Reynolds CF, Kupfer DJ et al:Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD) DSM-IV and ICD-10 categories a report from the APA NIMH DSM-IV Field Trial. Sleep 17:630-637, 1994
PubMed
3) Gilllin JC:Are sleep disturbances risk factors for anxiety depressive and addictive disorders? Acta Pschiatr Scand Suppl 393:39-43, 1998
 
4) Casper RC, Katz MM, Bowden CL et al:The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. Affect Disord 31:151-164, 1994
PubMed
5) Kennedy GJ, Kelman HR, Thomas C:Persistence and remission of depressive symptoms in late life. Am J Psychiatry 148:174-178, 199
 
6) Agargun MY, Kara H, Solmaz M:Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 58:249-251, 1997
PubMed
7) Fawcett J:Scheftner WA:Fogg L et al:Time-related predictors of suicide in major affective disorder. Am J Psychiatry 147:1189-1194, 1990
PubMed
8) Nowell PD, Buysse DJ:Treatment of insomnia in patients with mood disorders. Depress Anxiety 14:7-18, 2001
PubMed
9) Riemann D, Vbderholzer U, Berger M:Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 45 (suppl 1):S7-S12, 2002
 
10) Wilson S, Argyropoulos S:Antidepressants and sleep. A qualitative review of the literature. Drugs 65:927-947, 2005
PubMed
11) Pace-Schott EF, Gersh T, Silvestri R et al:SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10:129-142, 2001
PubMed
12) Monaca C, Boutrel B, Hen R et al:5-HT1 A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor citalopram on sleep studies in 5-HT1 A and 5-HT1B knockout mice. Neuropsychopharmacology 28:850-856, 2003
PubMed
13) Gillin JC, Jernajczyk W, Valladares-Neto DC et al:Inhibition of REM sleep by ipsapirone a 5-HT1 A agonist in normal volunteers. Psychopharmacology (Berl) 116:433-436, 1994
 
14) Dumon GJ, de Visser SJ, Cohen AF et al:Bio-markers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br Clin Pharamacol 59:495-510, 2005
 
15) Hicks JA, Argyropoulos SV, Rich AS et al:Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180:528-535, 2002
 
16) Lawlor BA, Newhouse PA, Balkin TI et al:A preliminary study of the effects of nighttime administration of the serotonin agonist m-CPP on sleep architecture and behavior in healthy volunteers. Biol Psychiatry 29:281-286, 1991
 
17) Ferini-Strambi L, Manconi M, Castronovo V et al:Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. J Psychopharmacol 18:417-422, 2004
PubMed
18) Lemoine E, Faivre T:Subjective and polysominographic effects of milnacipran on sleep in depressed patients. Hum Psychopharmacol 19:299-303, 2004
 
19) Argyropoulos SV, Wilson SJ:Sleep disturbances in depression and the effects of antidepressants. Intern Rev Psychiatry 17:237-245, 2005
 
20) Argyropoulos SV, Hicks JA, Nash JR et al:Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 120:179-190, 2003
PubMed
21) Armitage R, Trivedi M, Hoffmann R et al:Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depress Anxiety 5:97-102, 1997
PubMed

書評

最近チェックした商品履歴

Loading...